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Prólogo 
 
 
“O que fazemos por nós mesmos morre conosco.  
O que fazemos pelos outros e pelo mundo permanece e é imortal."  
Albert Pine 
 
Quem me conhece sabe que adoro desafios. Desde que ingressei no grupo de 
investigação de Neuro-Urologia de Translação no ano de 2006, o desafio foi constante e 
aliciante. 
Por essa altura, eu era apenas uma aluna da licenciatura em Biologia a realizar estágio 
de final de curso sem conhecimento do caminho que se abriria à minha frente. Nos primeiros 
dias de trabalho no Departamento de Biologia Experimental da Faculdade de Medicina do 
Porto, rapidamente despertei um forte interesse pelas neurociências e pela investigação, em 
grande parte graças às empolgantes descrições do Professor António Avelino acerca dos seus 
interesses científicos. 
O agradável ambiente e companheirismo sentido no dia-a-dia do departamento fez-
me sentir parte de um grupo com objectivos ambiciosos e motivadores que foram fulcrais no 
caminho que percorri até aos dias de hoje. 
Assim, uma dissertação de doutoramento apesar de possuir uma índole académica e 
científica, não representa apenas o resultado de várias horas de trabalho. O culminar do 
objectivo a que me propus é também fruto de contribuições de natureza diversa que não 
devem deixar de ser realçadas.  
Em 2008, foi-me proposto pelo Professor António Avelino estudar os mecanismos de 
acção da toxina botulínica, um desafio que abracei com bastante motivação. A ele agradeço a 
orientação científica e todo o conhecimento transmitido, base de todo o meu trabalho. 
Agradeço também os seus conselhos, ensinamentos e a sua amizade.  
Ao Professor Francisco Cruz, co-orientador destes trabalhos manifesto a minha 
admiração pessoal por si, pela sua sabedoria, integridade e capacidade de liderança do grupo 
de investigação que me acolheu. É, e será um exemplo a seguir. Agradeço toda a sua 
disponibilidade e ajuda em todos os momentos. 
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À Professora Célia Cruz um muito obrigada pela ajuda indispensável. Posso dizer que 
algumas das minhas conquistas as devo a ela. Obrigada pela compreensão e dinamismo que 
me fizeram perceber que, afinal, tudo é possível. Obrigada pelas palavras de amizade. 
Aos restantes elementos do grupo, agradeço a cumplicidade e bom-humor que nos 
caracteriza. Obrigada Ana Charrua, Sérgio Barros, Tiago Lopes e Raquel Oliveira pela ajuda e 
companheirismo essenciais ao longo de todo este trabalho. Obirgada pelas conversas, nem 
sempre científicas, recheadas de gargalhadas. Obrigada  Bárbara Frias, companheira diária 
deste desafio, pela amizade e partilha de tristezas e alegrias. Este trabalho nunca seria possível 
sem vocês. 
Um obrigada à Professora Deolinda Lima, directora do Departamento e do Programa 
Doutoral em Neurociências, por me permitir fazer parte desta grande família.  
Não poderei deixar de agradecer ao Professor Carlos Reguenga cujos sábios conselhos 
e bom-humor contagiante me deram a determinação  necessária para iniciar estes trabalhos. A 
sua  ajuda foi essencial em diversas alturas.  
A todos os meus colegas, ex-colegas e amigos do departamento, Gisela Borges, Patrícia 
Terra, Diana Sousa, Diana Nascimento, Ângela Ribeiro, Isabel Regadas, Margarida Oliveira, 
Mariana Matos, César Monteiro e José Castro, um obrigada por tornarem o meu dia-a-dia tão 
colorido e feliz.   
Gostaria também de reconhecer e agradecer a colaboração de todo o corpo técnico e 
do secretariado do departamento cuja ajuda foi tão importante. 
E porque a vida não é só trabalho... 
Agradeço às minhas amigas Raquel, Ana, Sara e Loide pelas nossas conversas, pela 
amizade, cumplicidade e partilha de sorrisos e lágrimas. A distância nunca separou a nossa 
amizade, e que assim seja pelos próximos anos.  
A todos os meus amigos que fazem questão de me fazer ver que existe vida “lá fora”. 
Obrigada pelas jantaradas, pelas loucuras e aventuras de fim-de-semana. Aos amigos 
socorristas da Cruz Vermelha. Obrigada por tornarem a minha vida muito pouco monótona. 
Aos meus pais e irmão, a quem devo tudo o que sou e construí até hoje. Sem o seu 
apoio incondicional nada disto seria possível. 
Por fim, agradeço à pessoa que diariamente me acompanhou neste desafio, o André. 
Pela sua paciência, compreensão e constante disponibilidade para me ouvir. Pelas suas 
palavras de inspiração nos dias bons e pelo seu ombro amigo nos dias menos bons. Por nunca 
me teres deixado desistir durante as mais terríveis tempestades. Obrigada.  
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Em obediência ao disposto no Decreto-Lei 388/70, Artigo 8º, parágrafo 2, declaro que efectuei 
o planeamento e execução do trabalho experimental, observação do material e análise dos 
resultados e redigi as publicações que fazem parte integrante desta dissertação. 
 
I. Coelho A, Dinis P, Pinto R, Gorgal T, Silva C, Silva A, Silva J, Cruz CD, Cruz F, Avelino A 
(2010) Distribution of the high-affinity binding sites and intracellular target of 
Botulinum Toxin type A in the Human Bladder. Eur Urol 57:884-890 
II. Coelho A, Cruz F, Cruz CD, Avelino A (2012) Spread of Onabotulinumtoxin/A after 
bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the 
marker of the toxin action. Eur Urol 61(6):1178-1184 
 
III. Coelho A, Cruz F, Cruz CD, Avelino A (2012) Effect of Onabotulinumtoxin/A on 
intramural parasympathetic ganglia: an experimental study on guinea pig bladder. J 
Urol 187(3): 1121-6 
IV. Coelho A, Oliveira, R, Rossetto, O, Cruz F, Cruz CD, Avelino A. (2013) Intrathecal 
administration of botulinum toxin type A improves urinary bladder function and 
reduces pain in rats with cystitis. (Submitted). 
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MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
12 
 
 
 
 
 
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
13 
 
 
 
Table of contents 
 
Abbreviations ...................................................................................................................... 15 
Abstract .............................................................................................................................. 17 
Resumo ............................................................................................................................... 19 
Introduction ........................................................................................................................ 21 
1. The discovery of botulinum toxin ................................................................................... 23 
2. The botulinum toxin family ............................................................................................. 25 
2.1 Mechanism of action ..................................................................................................... 26 
2.2 Regeneration of the neuromuscular junction after paralysis ....................................... 29 
3. Therapeutic uses of botulinum toxin .............................................................................. 30 
4. Botulinum toxin type A for lower urinary tract disorders ............................................... 31 
4.1 Lower urinary tract physiology ...................................................................................... 31 
4.2 Applications of botulinum toxin A in the lower urinary tract ....................................... 34 
4.3 Mechanisms of action of botulinum toxin A in the LUT ................................................ 35 
5. Botulinum toxin A in the central nervous system ............................................................... 38 
Goals ................................................................................................................................... 39 
Publications ......................................................................................................................... 41 
Publication I ............................................................................................................................. 43 
Publication II ............................................................................................................................ 53 
Publication III ........................................................................................................................... 63 
Publication IV .......................................................................................................................... 71 
Final Considerations ............................................................................................................ 89 
Conclusions ......................................................................................................................... 97 
References ........................................................................................................................ 101 
 
 
 
 
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
14 
 
 
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
15 
 
 
Abbreviations 
 
Abbreviations used in “Introduction”, “Final considerations” and “Conclusions” 
 
Abobot/A – abobotulinum toxin A 
BDNF – brain derived neurotrophic factor 
BoNT – botulinum toxin 
BoNT/A – Botulinum toxin type A 
BPS/IC – bladder pain syndrome/interstitial cystitis 
CGRP – calcitonin gene-related peptide 
DO – detrusor overactivity 
FDA – food and drug administration 
IDO – idiopathic detrusor overactivity 
Incobot/A – incobotulinum A 
IT - Intrathecal 
LUT – lower urinary tract 
NDO – neurogenic detrusor overactivity 
NGF – nerve growth factor 
NO – nitric oxide 
OAB – overactive bladder 
Onabot/A – onabotulinum A 
PAG – periaqueductal grey matter 
PMC – pontine micturition centre 
SCI – spinal cord injury 
SNAP-25 – synaptosomal-associated protein of 25 kDa 
SNARE – soluble N-ethylmaleimide sensitive fusion attachment receptor 
SP – substance P 
SV2 – synaptic vesicle 2 
TRPV1 – transient receptor potential vanniloid 1 
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Abstract  
 
Botulinum toxin type A is successfully used in the treatment of lower urinary tract 
dysfunctions in which hyperactivity of the detrusor is a main symptom. The use of this toxin in 
neuromuscular disorders relies on its ability to cleave the SNAP-25 protein impairing the 
release of acetylcholine on the neuromuscular junction. This mechanism of action has been 
deeply studied in the skeletal muscle however, its action on the detrusor smooth muscle 
remained to be elucidated. Due to the complexity of urinary bladder neuronal pathways and to 
the multifactorial etiology of lower urinary tract disorders, many questions were still 
unanswered. In the present work we give new insights on the targets of action of botulinum 
toxin as well as its effects in the urinary bladder. 
In Publication I a detailed description of the distribution of the receptor and the 
intracellular target of botulinum toxin A was performed in the human bladder. Both proteins 
were present in all bladder nerve types with a total co-localization. With this work we could 
show that all the human urinary bladder nerve fibers could be targeted by botulinum toxin A. 
Furthermore, in Publication II we decided to investigate the exact location of 
botulinum toxin activity, administrating the toxin in the bladder of an animal model. We used 
the cleaved form of the SNAP-25 to detect the toxin action. The cleaved protein was detected 
and quantified in the three bladder nerve types demonstrating that all fibers are targets of the 
toxin. In addition we compared different administration forms of the toxin and tested the 
importance of some dilution factors. We observed that the volume of injection is crucial for 
the effectiveness of botulinum toxin A in the bladder. 
Another aspect of this issue was addressed in Publication III. We explored the effect of 
botulinum toxin in the parasympathetic ganglia since in the human and guinea-pig bladders 
they are located within the bladder wall. Thus, intramural administration of the toxin directly 
affects the preganglionic synapse of these ganglia besides the effect on the postganglionic 
synapse at the muscle bundles. 
Finally, in Publication IV we decided to investigate the effect of botulinum toxin A in 
an animal model where bladder pain and hyperactivity were present. In addition, we wanted 
to test the direct effect of the toxin in the spinal cord. Thus we used the cyclophosphamide-
induced bladder inflammation model to analyze the effect of intrathecal botulinum toxin. With 
this work we found that the toxin counteracts pain behavior and bladder hyperactivity induced 
by cyclophosphamide. We also observed a direct effect on the expression of neuronal 
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activation markers that are usually increased in this model. Furthermore we detected the 
presence of cleaved SNAP-25 not only throughout nerve fibers of the L6 spinal cord segment 
but also in the urinary bladder. Overall with these results we could say that the intrathecal 
administration of botulinum toxin A is effective in the treatment of bladder inflammatory pain 
and that this route of administration may be further explored for intractable forms of pain. 
Taken together, the studies comprised in the present dissertation give new insights 
about the mechanisms of botulinum toxin action on the detrusor muscle as well as in the 
central nervous system. With clinical importance, the present findings could be directly applied 
in the improvement of treatments for bladder dysfunctions. 
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Resumo 
 
A toxina botulínica do tipo A tem vindo a ser utilizada com sucesso em disfunções do 
tracto urinário baixo cuja hiperactividade do detrusor é o sintoma principal. O uso desta toxina 
em doenças neuromusculares tem por base a sua capacidade para clivar a proteína SNAP-25 
impedindo a libertação de acetilcolina na junção neuromuscular. Este mecanismo de acção 
tem vindo a ser estudado em profundidade no músculo esquelético contudo, a sua acção no 
músculo liso ainda não foi clarificada. Dada a complexidade das vias neuronais da bexiga e 
tendo em conta a etiologia multifactorial das disfunções do tracto urinário baixo, várias 
questões estão ainda por responder. No presente trabalho são fornecidos novos dados 
relativos aos alvos de acção da toxina botulínica assim como os seus efeitos na bexiga. 
Na Publicação I foi efectuada uma descrição detalhada da distribuição do receptor e 
do alvo intracelular da toxina botulínica do tipo A na bexiga humana. Ambas as proteínas 
estavam presentes em todos os tipos de fibras da bexiga com total co-localização. Com este 
trabalho foi possível mostrar que todas as fibras nervosas da bexiga humana podem ser alvo 
de acção da toxina botulínica do tipo A. 
Na Publicação II decidimos investigar a localização exacta da acção da toxina botulínica 
administrando-a na bexiga de um modelo animal. Utilizamos a forma clivada da SNAP-25 para 
detectar a actividade da toxina. A proteína clivada foi detectada e quantificada nos três tipos 
de fibras nervosas da bexiga demonstrando que todas as fibras eram alvos da toxina. Além 
disto, comparamos diferentes modos de administração da toxina e testamos a importância de 
alguns factores de diluição. Observamos que o volume da injecção é crucial para a eficácia da 
toxina botulínica do tipo A na bexiga. 
Um outro aspecto deste tema foi abordado na Publicação III. Exploramos o efeito da 
toxina botulínica nos gânglios parassimpáticos tendo por base que no humano e no cobaio 
estes gânglios se encontram na parede da bexiga. Assim, verificamos que a administração 
intramural de toxina afecta directamente a sinapse pré-ganglionar destes gânglios para além 
do seu efeito pós-ganglionar exercido na sinapse estabelecida com os feixes musculares. 
Finalmente, na Publicação IV decidimos investigar o efeito da toxina botulínica do tipo 
A num modelo animal onde a dor e a hiperactividade da bexiga estivessem presentes. Além 
disto, pretendemos testar o efeito directo da toxina na medula espinal. Assim, utilizamos o 
modelo de inflamação da bexiga induzida pela ciclofosfamida para analisar o efeito da injecção 
intratecal de toxina botulínica. Com este trabalho descobrimos que a toxina contraria o 
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comportamento nociceptivo e a hiperactividade vesical induzidas pela ciclofosfamida. Também 
observamos um efeito directo na expressão de marcadores de activação neuronal que estão 
habitualmente aumentados neste modelo. Detectamos a presença de SNAP-25 clivada não 
apenas em fibras nervosas dispersas pelo segmento L6 da medula espinal mas também na 
bexiga. Com este conjunto de resultados podemos afirmar que a administração intratecal de 
toxina botulínica do tipo A é eficaz no tratamento da dor inflamatória da bexiga e que esta via 
de administração poderá ser explorada para tratamento de casos de dor intratável. 
Os estudos compreendidos na presente dissertação trazem novos detalhes sobre o 
mecanismo de acção da toxina botulínica no músculo detrusor assim como no sistema nervoso 
central. Com relevância clínica, estas descobertas poderão ser directamente aplicadas na 
melhoria dos tratamentos para disfunções da bexiga. 
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1. The discovery of botulinum toxin 
 
Botulinum toxins are among the most deadly natural toxins known and have been 
following mankind since very early times. Botulinum toxin is responsible for botulism, a deadly 
intoxication caused by the ingestion of food contaminated with the bacteria Clostridium 
botulinum. Since the first description of the disease, the toxin evolved from poison to therapy 
in a controversial as well as fascinating journey. 
The first botulism-like symptoms are reported from the 10th century, when the 
Byzantine Emperor Leo IV banned the consumption of blood sausages after the occurrence of 
several deaths. However, the medical knowledge of the time was not enough to characterize 
the disease. Therefore, the first reports of botulism appeared only in the 18th century (1).  
For centuries storage conditions used to preserve food provided ideal environments 
for the presence and growth of anaerobic organisms. In 1793, several cases of a fatal food 
poisoning appeared in the region of Wurttemberg after a decrease of the sanitary 
measurements triggered by the poverty during Napoleonic wars (1795-1813) (2). The first 
symptoms reported included gastrointestinal problems, diplopia, mydriasis and progressive 
muscular paralysis, which were studied by researchers of the University of Tübingen (3). In 
1802, after an increasing number of deaths, the link between the consumption of sausages 
and a possible food poisoning reappeared and a public announcement was released to alert 
the population. 
Between 1817 and 1820, with the spread of the disease, the German physician 
Justinus Kerner (1786-1862) decided to investigate the cases. He accurately described all the 
clinical symptoms of more than 200 victims of what we nowadays call botulism. The symptoms 
included disturbances of the autonomic nervous system, like mydriasis, reduction of lacrimal 
and salivary glands secretion, gastrointestinal and urinary bladder paralysis. Kerner stated that 
the toxin was being developed in sausages under anaerobic conditions, that it was interrupting 
the motor and autonomic nervous system transmission and that it was strong enough to be 
lethal even in very small doses (4). In a visionary way, Kerner proposed for the first time a 
possible therapeutic application for the lethal agent, being considered the godfather of 
botulism research (4).  
So far, botulism had been accurately described even before the identification of the toxin 
and nothing important was added to Kerner’s work until the 19th century (2). The following 
significant step was given by the microbiologist Emile Pierre van Ermengen who established for 
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the first time a correlation between several cases of intoxication and an anaerobic 
microorganism. Actually, he was the pioneer on the isolation of the bacteria Clostridium 
botulinum and characterization of its toxin (5). 
 
 
18th 
century 
First reports of food-borne botulism in Europe 
1817-1822 Justinus Kerner - experiments with the causative agent of botulism, preliminary 
experiments with animals, systematic descriptions of its clinical effect, theoretical 
considerations and speculations about its therapeutical use 
1870 Müller – referred to the “sausage poisoning” as “botulism” form the latin word “botulus” 
which means sausage  
1895-1897 Emile Pierre van Ermengen - identification of C. botulinum as the causative agent of 
botulism  
1910 Leuchs – discovery of the second serologically different botulinum toxin serotype 
1919 Georgina Burke – designation of the two serologically different strains as botulinum 
toxin types A and B 
1920 Herman Sommer – isolation and purification of botulinum toxin type A as a stable acid 
precipitate 
1922 Bengston and Seddon - identification of botulinum toxin type C  
1928 Meyer and Gunnison - identification of botulinum toxin type D 
1936 Bier - identification of botulinum toxin type E 
1941-1946 Edward Schantz - purification of botulinum toxin type A in a crystalline form 
1949-1950 Arnold Burgen and Vernon Brooks - description of the temporary paralysis induced by 
botulinum toxin blockade of acetylcholine release from the neuromuscular junction 
1960 Moller and Scheibel - identification of botulinum toxin type F 
1968 Alan Scott and Edward Schantz – botulinum toxin experiments with monkeys to 
determine its use in strabismus 
1970 Gimenex and Ciccareli - identification of botulinum toxin type G 
 
Table 1: Historical timeline of the discovery and study of botulinum toxin before its therapeuthic 
application (2, 3). 
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2. The botulinum toxin family 
 
Botulinum toxins (BoNT) are produced by Clostridium botulinum, a Gram-positive, spore-
forming, anaerobic bacillus that is ubiquitously found in the environment (5). The toxins 
produced by these rod-shaped bacteria are some of  the most powerful naturally occurring 
compounds known, with lethal doses for humans around 1 ng/kg of body weight (6). 
C. botulinum produces seven immunologically distinct types of BoNTs, isolated and 
identified as serotypes from A to G (7). Other bacteria such as Clostridium butyricum and 
Clostridium baratii also produce two types of BoNTs, types E and F respectively. The seven 
serotypes are homologous and each one is characterized by particular toxicity properties and 
different molecular targets.  
BoNTs are initially synthesized as inactive, single-chain polypeptides with a molecular 
weight of approximately 150 kDa (8). The protein is post-translationally proteolyzed by 
clostridial proteases expressed intra or extracelularlly to form an active dichain that possesses 
maximum biological activity.  The active molecule is composed by a heavy chain of 100 kDa 
and a light chain of 50 kDa linked by a disulfide bridge and non covalent interactions 
associated with a zinc atom (9).  
 
 
Figure 1: The single chain polypeptide of 150 kDa is proteolyzed to be on its active form. The activated 
dichain is composed by a light chain of approximately 50 kDa and a heavy chain of 100 kDa linked by a 
disulfide bridge. The light chain contains the catalytic properties and the heavy chain comprises the 
translocation and the binding domain. Adapted from Lacy et al (8).  
 
 
The molecular structure of the active dichain reveals three distinct functional domains of 
similar size named as binding, translocation and catalytic domains (10, 11). The heavy chain 
comprises a C-terminal binding domain and an N-terminal translocation domain. The light 
chain is the catalytic domain located in the N-terminal portion of the molecule and is 
characterized by its zinc-dependent endopeptidase activity (Figure 1).  
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2.1 Mechanism of action 
 
Botulinum toxins usually enter the human organism through oral ingestion of 
contaminated food. In its natural environment, BoNTs interact with nontoxic proteins, to form 
a complex progenitor toxin of 300 to 900 kDa. These non-toxic proteins increase BoNTs 
stability, protecting them from the acidic conditions of the gastrointestinal tract and allowing 
their passage through the intestinal epithelium into the blood circulation (12). Once inside the 
bloodstream, BoNTs travel until their target cells acting through a multi-step intoxication 
process composed by four stages: binding, internalization, translocation to the cytosol and 
SNARE cleavage (13), as detailed below. 
 
2.1.1 Binding to the target cell 
 
BoNTs attach to their target cells through a two-receptor phenomenon that involves a 
low and a high affinity receptor (14). The toxin heavy chain specifically interacts with 
membrane glicolipids called polysialogangliosides which are particularly abundant on the cell 
surface of neuronal cells (15, 16). BoNT/A is known to exclusively interact with the GT1b type 
of gangliosides (17). The low affinity complex toxin-ganglioside forms a mesh that accumulates 
the toxin on the plasma membrane surface. This mesh lingers the toxin on the cell membrane 
plane until it interacts with the high affinity binding site. The high-affinity receptor for BoNT/A 
has recently been identified as the synaptic vesicle protein 2, SV2 (18, 19), expressed in the 
luminal surface of synaptic vesicles (20). During exocytosis, vesicles fuse with the plasma 
membrane exposing their luminal side to the extracellular space. Consequently, SV2 is exposed 
and allowed to contact with the toxin captured by the ganglioside mesh (21). BoNT/B, on the 
other hand, has the ability to bind both synaptotagmin II and the ganglioside GD1a at the same 
time, increasing its stability to specifically affect neuronal cells (22). Toxin binding to high-
affinity receptors is serotype-specific and the identity of the receptors for all BoNT serotypes is 
still unknown. 
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2.1.2 Internalization – receptor-mediated endocytosis 
 
Internalization of botulinum toxins occurs during membrane retrieval, after exocytosis 
of synaptic vesicles (18, 19). According to this process, the lumen of the synaptic vesicles is 
temporarily exposed to the synaptic cleft, allowing the contact with the accumulated toxin. 
The cell membrane is then recycled and internalized to form a new synaptic vesicle, dragging 
the toxin attached to its receptor (23). Very active cells, like the cholinergic neurons of the 
neuromuscular junction, are frequently releasing acetylcholine by exocytosis. Thus, as more 
SV2 is exposed, more BoNT/A internalization occurs in an activity-dependent process already 
shown in in vitro studies with hippocampal neurons and in in vivo studies using the rat phrenic 
nerve  (18, 23, 24). 
 
2.1.3 Translocation 
 
After internalization, a pH decrease inside the endosome induces a structural 
rearrangement of the toxin. This phenomenon increases the protein hydrophobicity, 
facilitating the penetration of the molecule in the lipid bilayer in a way that promotes the 
translocation of the light chain to the cytosol (25). Once the light chain contacts the cytosol, 
the disulfide bridge is broken, allowing the release of the catalytic domain into the cytosol 
(26). The hypothesis that botulinum toxins are released to the cytosol through a pH-induced 
translocation is currently accepted, however, the exact mechanism of translocation is still a 
matter of debate.  
 
2.1.4 SNARE cleavage 
 
The release of neurotransmitters involves a complex process in which stimulation of 
the nerve fiber causes a depolarization that activates voltage-dependent calcium channels and 
a consequent influx of calcium into the nerve terminal. The increase of calcium concentration 
causes synaptic vesicles to fuse with the plasma membrane, thereby releasing 
neurotransmitters at the synaptic cleft (27) (28). 
Soluble N-ethylmaleimide-sensitive fusion attachment protein receptor (SNARE) 
proteins mediate the fusion of the synaptic vesicle with the plasma membrane and are 
classified as vesicle-associated SNAREs (v-SNAREs) and target membrane SNAREs (t-SNAREs) 
located at the plasma membrane. The v-SNARE is a protein known as synaptobrevin or vesicle-
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
28 
 
associated membrane protein (VAMP) that is attached to the synaptic vesicle membrane via its 
C-terminal region. The t-SNAREs comprise two proteins located at the cell membrane: the 
synaptosomal associated protein of 25 kDa (SNAP-25) and syntaxin. When the synaptic vesicle 
approaches the plasma membrane, the three proteins interact to form the SNARE complex, 
which plays an essential role in exocytosis. 
Once released to the cytosol, the BoNT light chains, which have zinc-dependent 
endopeptidase activity (29), specifically target one of the SNARE proteins (30), inhibiting 
vesicle exocytosis. 
 
Figure 2: Intracellular targets of botulinum toxins. Once inside the cell the light chain of each botulinum 
toxin has the ability to cleave, specifically, one of the SNARE complex proteins. VAMP is cleaved by 
serotypes B, D, F and G. SNAP-25 is cleaved by botulinum toxins A, C and E. Syntaxin is cleaved only by 
serotype C. Cleavage of one of these proteins will inhibit the vesicle exocytosis. Adapted from Meunier 
et al (31).  
 
Each light chain of a BoNT serotype selectively targets one SNARE protein (Figure 2). 
BoNT/A cleaves SNAP-25 by removing nine aminoacids from the C-terminus while Bont/E also 
cleaves SNAP-25 but removing 26 aminoacids (32). The other serotypes are able to cleave 
VAMP and syntaxin.  
Cleavage of individual SNARE proteins does not prevent the SNARE complex formation, 
but results in a nonfunctional complex in which the coupling between Ca+ influx and fusion is 
disrupted (33). Calcium has a crucial role in the process of neurotransmitter release inhibition 
as the increase of calcium concentration in the synaptic terminal partially counteracts the toxin 
effect (31). Histological analyses showed that an accumulation of synaptic vesicles occur in the 
cytosolic side of the plasma membrane as a direct consequence of the proteolytic activity 
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described above. The toxin does not affect Ach synthesis or storage nor the electrical 
conduction along the nerve fiber (25, 34).  
This multi-step mechanism of action illustrates the toxin’s effect on its most studied 
target, the neuromuscular junction. Here, botulinum toxin interferes with the signaling 
between α and γ motor neurons and extrafusal and intrafusal muscle fibers (35, 36). Besides 
botulinum toxin action on the striated muscle, it is nowadays known that the toxin also acts on 
the smooth muscle and on other cell types through the same mechanism. 
 
2.2 Regeneration of the neuromuscular junction after paralysis 
 
During BoNT intoxication in the striated muscle, inhibition of exocytosis occurs and the 
affected nerve terminals lose their functionality. Unlike what happens during denervation, the 
contact between nerve terminal and muscle fiber is maintained without loss of motor axons. 
This process is temporary and lasts only for a few months. Histological studies showed that the 
recovery process happens in two steps. Initially, a compensatory nerve sprouting occurs and 
an extensive network of new synapses develops along with an increased vesicle recycling rate. 
Later, when the exocytosis of the main terminal is recovered, the previously formed branches 
recess and functionality returns to normal (37). The recovery time varies according to the toxin 
serotype and local of action. 
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3. Therapeutic uses of botulinum toxin 
 
 
Of the seven different strains of botulinum toxin only two, serotypes A and B, are 
commercially available. Serotype A is commercially available as Botox (Onabotulinum toxin A – 
Onabot/A, produced by Allergan Inc, Irvine, CA, USA), Dysport (Abobotulinum toxin A – 
Abobot/A, produced by Ipsen Ltd, Slough, Berks, UK) and Xeomin (Incobotulinum toxin A – 
Incobot/A from Merz Pharmaceuticals, Frankfurt, Germany). Other recent BoNT/A 
formulations were also created as Prosigne (Lanzhou Biological Poducts, Lanzhou, China) and 
PurTox (Mentor Corporation, Madison, WI, USA). Serotype B is available as 
Neurobloc/Myobloc (Solstice Neurosciences Inc, Malvern, PA, USA) (38). All therapeutic 
botulinum toxin preparations are composed by the actual toxin (light and heavy chains) plus 
non-toxic proteins added by the pharmaceutical company (38). Each BoNT formulation has its 
own characteristics because isolation, extraction and purification processes are different. 
Concerning BoNT/A there are two currently approved methods that can be used to estimate 
the potency of a specific BoNT/A brand. The first method is the mouse lethal dose (LD50), 
which corresponds to the mass of toxin that kills 50% of the mice. A more recently approach is 
a cell-based assay in which human neuroblastoma cells are used to measure the concentration 
of toxin required to cleave 50% of the SNAP-25. However, the conversion of clinical doses of 
different BoNT/A brands to be used in LUT disorders were never performed. Thus, even among 
preparations of the same serotype, doses are not comparable and not interchangeable (39, 
40).  
Onabotulinum toxin A is the most studied formulation so far and comparison studies 
showed that its activity is stronger and has a more prolonged effect than the others (41). It has 
become widely known mainly for cosmetic use but it is undoubtedly considered a valuable and 
evolving tool in the treatment of various neurological disorders. Therefore, BoNT/A is the main 
focus of the present thesis and its usefulness in urology will be discussed deeper along the 
following chapters. 
The demonstration that the inhibition of neurotransmitter release at the striated 
muscle is followed by a functional recovery of the neuromuscular junction as well as the 
improved techniques of biochemical purification of BoNTs, provided a solid basis for the 
rapidly growing use of these toxins in the therapy of human diseases caused by excessive 
acetylcholine release. 
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Alan Scott used botulinum toxin type A for the first time in 1968 for the treatment of 
human pathologies reporting the therapeutic effects in strabismus (42, 43). Since then, 
botulinum toxin had been used in the management of several disorders where a reversible 
inhibition of a cholinergic terminal activity is desired. In 1989, the Food and Drug 
Administration (FDA) approved the use of BoNT/A for the treatment of blepharospasm, 
cervical dystonia and strabismus (44). Nowadays, toxin is approved for the treatment of a 
variety of movement disorders like spasticity, hypersecretory disorders such as hyperhidrosis 
(45), gastrointestinal disorders such as achalasia (46) and many cosmetic applications such as 
wrinkles or facial assymetrics. The use of the toxin in the lower urinary tract will be addressed 
in the following section. 
 
4. Botulinum toxin type A for lower urinary tract disorders 
 
4.1 Lower urinary tract physiology 
 
The lower urinary tract (LUT) components comprise the urinary bladder, the urethra 
and the urethral sphincter. The bladder is a hollow and elastic organ whose wall is composed 
by bundles of smooth muscle, named detrusor muscle, separated by connective tissue that 
provides the organ great compliance. The urethra and the urethral sphincter are surrounded 
by striated muscle, which is in part under voluntary control of the somatic nervous system. 
The coordination of all these components is a complex and highly distributed process 
called micturition which involves multiple pathways from spinal and supraspinal levels and the 
peripheral nervous system. Recent findings from functional brain imaging experiments 
suggested the midbrain periaqueductal gray (PAG) as the main coordination area that 
integrates somatic, autonomic and sensory information with a crucial role in bladder control 
and functioning (47). PAG coordination involves modulation of the pontine micturition center 
(PMC) of the brain stem and the three sets of peripheral neuronal circuits that include the 
sympathetic, the parasympathetic and the somatic nervous system (48).  
The sympathetic innervation originates at the lower thoracic level and upper lumbar 
segments of the spinal cord (T10 to L2), and travels through preganglionic fibers until the 
inferior mesenteric ganglion and pelvic ganglia. Postganglionic fibers follow the hypogastric 
and pelvic nerves until the bladder. Parasympathetic neurons are located in the sacral 
parasympathetic nucleus of the spinal cord segments S2 to S4. Their axons pass along the 
pelvic nerve and synapse with postganglionic nerves of the parasympathetic ganglia located 
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within the bladder wall. Somatic innervation arises from the ventral horn of the sacral 
segments S2 to S4, an area called Onuf’s nucleus, and through the pudendal nerve innervates 
the striated muscle of the external urethral sphincter (Figure 3). Finally, sensory afferent 
innervation can be found in the three previous described nerves and transmit information 
from the LUT to the lumbosacral spinal cord through the dorsal root ganglia (pudendal and 
pelvic nerves) and the hypogastric nerve. 
 
The normal micturition reflex is mediated by a supraspinal pathway that passes 
through relay centers of the brain. These cortical areas are activated differently during the 
filling or storage phase and in the emptying phase in a coordinated fashion that resembles an 
on-off switch (47). During the storage phase afferent impulses convey information through the 
pelvic nerve to the central nervous system, specifically to the PAG, which relay information to 
higher brain regions. The PAG-PMC output is responsible for the activation of sympathetic 
innervation that keeps the detrusor muscle relaxed. This is achieved by inhibition of the 
parasympathetic pathways at spinal and ganglion levels thus allowing the accumulation of 
urine. In addition, somatic innervation provides excitatory innervation to the striated muscles 
of the urethral sphincter, preventing bladder emptying (49). Bladder filling occurs with a 
relatively low increase of pressure. Once the volume of urine reaches a critical level and 
luminal pressure is high, bladder sensory afferent nerve fibers and its mechanoreceptors 
convey the information of bladder fullness to supraspinal areas, generating conscious bladder 
sensations. The circuits of the PAG-PMC complex are responsible for switching the neuronal 
circuits in order to start the voiding phase. Thus, the micturition reflex is initiated by 
decreasing the sympathetic activity and increasing the parasympathetic one (50). 
Parasympathetic stimulation of the detrusor induces its contraction and simultaneously 
relaxes the urethral sphincter, initiating bladder emptying. During micturition, the activity of 
the somatic system on the urethral sphincter is temporarily inhibited allowing its relaxation 
(51). 
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Figure 3: Schematic representation of LUT innervation. Urinary bladder is controlled by parasympathetic, 
sympathetic and sensory fibers which convey the information through pelvic, hypogastric and pudendal nerves, 
respectively. Adapted from Kanai et al (52). 
 
Another bladder component that has a crucial role in the modulation of bladder 
activity is the urothelium. This structure is not only a passive barrier between the urine and the 
underlying tissues, it rather exhibits signaling properties that make it act as a sensory organ 
(53). Urothelial cells express nicotinic, muscarinic, adrenergic and vanilloid receptors that 
respond to mechanical and chemical stimuli. These cells also release ATP, prostaglandins, nitric 
oxide (NO), nerve growth factor (NGF) and brain-derived neurotrophic factor, substances that 
have excitatory and inhibitory actions on the afferent neurons. In addition, the ATP released 
from the urothelium can act on purinergic receptors expressed on cholinergic fibers 
modulating detrusor contractility.  
Overall, urothelial cells exhibit specific properties that allow them to perceive chemical 
and mechanical changes in the environment and establishing a crosstalk between urothelium, 
the surrounding and intertwining nerve fibers and smooth muscle of the bladder wall. 
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Therefore, the normal micturition reflex is the result of a complex interaction between 
all LUT components in which any alteration could contribute to LUT dysfunctions (51, 54). 
 The development of therapeutic strategies for urinary bladder disorders is, nowadays, 
dependent on a better understanding of bladder physiology. Current treatments were 
designed aiming to restore normal bladder function. However, since the etiology of many 
pathologies is not completely clear, the majority of therapies simply improve LUT symptoms 
without any effect on the cryptogenic origin.  
 
4.2 Applications of botulinum toxin A in the lower urinary tract 
 
 Onabotulinum toxin A has been used in the urology field since 1988, after its first 
injection into the external urinary sphincter, to manage detrusor sphincter dyssynergia in 
spinal cord injured (SCI) patients (55).  A few years later, in 2000, Brigitte Schurch and co-
workers described the first application into the detrusor muscle in SCI patients with successful 
results that demonstrated a significant increase in the mean maximum bladder capacity (56).  
Since then, Onabot/A became a safe and effective tool for the treatment of lower 
urinary tract pathologies being used to treat urinary dysfunctions such as detrusor overactivity, 
overactive bladder, bladder pain syndrome/interstitial cystitis and benign prostate hyperplasia, 
among others, with very good outcomes even in children (57-59).  
Its main urological target symptom is incontinence associated with urgency and 
frequency due to detrusor overactivity (60). Actually, the efficacy of Onabot/A treatment for 
LUT disorders is nowadays well documented and safety profiles are good. Very recent phase 3 
clinical trials reported positive outcomes about Onabot/A treatment for OAB and NDO. These 
studies culminated on the recent FDA approval of 100U of Onabot/A for the management of 
idiopathic OAB and 200 or 300U for NDO. In OAB patients refractory to anticholinergics, 
Onabot/A significantly decreased the number of urinary incontinence episodes per day 
compared to placebo. Other OAB symptoms such as urgency and nocturia were also 
significantly reduced. Patients reported an improvement of their general quality of life in 
addition with positive responses on the treatment benefit scale (61, 62). Concerning NDO 
patients, Onabot/A benefits were observed by 2 weeks after its application, mainly concerning 
incontinence episodes. Other improvements were observed in the maximum cystometric 
capacity, maximum detrusor pressure during first involuntary detrusor contraction and in the 
incontinence quality of life score (63, 64). The most common side effects were urinary tract 
infection and urinary retention. The urinary tract infections were uncomplicated without upper 
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urinary tract involvement in 15.5% of patients and usually due to an increase in post-void 
residual volume (61-64). Urinary retention occurred in approximately 5-7% of OAB patients 
and 40% of NDO patients leading to the need of catheterization (61-64). Discontinuation rates 
are less than 2%, very low when compared to other treatments (65).  
Other studies were also completed exploring its potential effect on other pathologies 
such as BPS/IC. The efficacy of Onabot/A was evaluated in refractory BPS/IC patients and the 
toxin also showed to be very effective. Pain, urgency and urodynamic parameters such as 
frequency, bladder volume to first pain and maximal cystometric capacity seemed to improve 
after toxin administration. The improvement of LUT symptoms lasted for 9 months in around 
50% of patients who also reported a significant improvement in their quality of life (66).  
Although many progresses have been done in the field, there is still a lack of 
standardized protocols for Onabot/A injection. The variety of existent studies are not 
consistent concerning the precise area of injection, the number of injections, the dilution 
volumes and even the ideal dose for different pathologies (67). In addition, some studies 
suggest intravesical instillation as a less invasive option for Onabot/A administration (68). Even 
though already widely used, this variety of protocols makes it difficult to conclude about the 
optimal approach for toxin administration urging the need of systematic studies.   
 
4.3 Mechanisms of action of botulinum toxin A in the LUT  
 
As described above, it is well documented that botulinum toxin acts on the cholinergic 
terminal of the neuromuscular junction, blocking the ACh release and consequently impairing 
the contraction of the striated muscle. On the other hand, it is nowadays clear that the toxin 
also acts on the smooth muscle of the urinary bladder, where a complex nerve plexus is 
present. The exact mechanism of BoNT/A on the modulation of this intricate bladder control is 
still a matter of debate and several questions need to be answered.  
From a microscopic point of view, no relevant histological or ultrastructural changes 
were observed after treatment. After Onabot/A treatment, NDO and idiopathic OAB patients 
showed no TUNEL-positive cells, indicating no signs of apoptosis (69). Detrusor ultrastructure 
also remains intact without alterations on muscle cells structure, width of intercellular space 
and number or type of muscle cell junctions (70). Histological analysis showed no differences 
in the expression of myofibroblasts and no significant signs of inflammation or fibrosis before 
and after treatment of NDO and IDO patients (71, 72). Sprouting of smooth muscle terminal 
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axons is scarce showing a major difference when compared to the toxin effect on striated 
muscle (70).  
In the detrusor, BoNT/A is known to decrease the release of ACh like in the striated 
muscle since it decreases the unstable contractions of the detrusor during IDO. Studies 
performed in animals showed that Onabot/A effect resulted in a selective paralysis of the low-
grade contractions while still allowing the high-grade contractions that initiate micturition (73). 
Other studies also showed that BoNT/A could inhibit the evoked release of ACh and ATP from 
rat and guinea-pig bladder strips (74-76). A recent study corroborated this effect of the toxin 
on efferent fibers of the detrusor. The authors used spinal cord transected mice to show that 
Onabot/A elicits its suppressant effects on NDO by blocking neurotransmitters release from 
efferent nerve terminals. Interestingly, any effect was observed in terms of intrinsic contractile 
activity of the detrusor as well as in the intracellular Ca2+ transients responsible for these 
contractions (77).  
The Onabot/A effect has been also previously described in sensory fibers (78). The 
biochemical mechanisms and locals of action are similar in these nerve fibers when compared 
to the ones observed in motor neurons. The difference is found in the pharmacological effect 
and it is due to the blockade of peripheral release of neuropeptides that act by sensitizing 
nerve terminals involved in pain perception. Bladder afferent nerve fibers express numerous 
receptors such as the vanniloid receptor TRPV1 (79) and the purinergic receptor P2X3 (80). 
P2X3 has a role in nociception, especially in inflamed tissue (81). TRPV1, a noxious stimulus 
integrator, has a specific role in pain perception namely thermal hiperalgesia and inflammatory 
pain (82). The expression of both receptors is increased in LUT disorders thus increasing 
bladder sensitivity (81, 82). Studies performed in human bladders showed that Onabot/A 
reduces the expression levels of both receptors in suburothelial nerve fibers (83). Actually, in 
vitro studies showed that BoNT/A blocks PKC-induced membrane expression of TRPV1 (84). 
Thus, it is expected that the decrease of both receptors induced by the toxin could suppress 
bladder sensory activity and prevent the activation of the micturition reflex during bladder 
filling. 
The research about other mechanisms of action of BoNT/A has been increasing on 
animal models of disease especially around an antinociceptive effect of the toxin. For example, 
in a formalin-induced inflammatory pain model, Onabot/A was shown to reduce the formalin-
evoked glutamate release from primary sensory neurons of the rat paw. In the same studies, 
formalin-induced Fos-like immunoreactivity in the dorsal horn, was also reduced by 
subcutaneous Onabot/A (85). Furthermore, in an animal model of neuropathic pain, Onabot/A 
induced a long-lasting antinociception induced by sciatic nerve injury (86).  
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Bladder sensory afferents also express neuropeptides like CGRP and SP, which are 
inflammatory mediators released in response to noxious stimulation. During OAB and BPS/IC, 
these neuropeptides are overexpressed suggesting that they have a role in the 
pathophysiology of these dysfunctions (87, 88). Pre-clinical studies showed that BoNT/A 
reduced pain responses and inhibited CGRP and SP release from bladder afferent terminals 
(89-91) suggesting an effect of the toxin in bladder pain. Furthermore, Onabot/A also 
modulates the urinary levels of neurotrophins that are usually increased in OAB and BPS/IC 
patients (92). Intramural injections of the toxin counteracted the increase of NGF levels 
associated with idiopathic and neurogenic DO as well as BPS/IC patients (66, 93). Thus the 
antinociceptive effect of BoNT/A has been also studied in the urology field due to its potential 
role in the decrease of hiperalgesia associated with LUT pathologies. 
Finally, some authors suggested that BoNT/A has the capacity to affect non-neuronal 
cells like the urothelial ones, therefore modulating afferent nerve excitability. Indeed, BoNT/A 
was shown to reduce ATP and increase nitric oxide released from urothelial cells, 
counteracting the altered levels during conditions like chronic inflammation or spinal cord 
injury (94, 95). This fact might be extremely important for sensory transmission since ATP 
released from the urothelium seems to activate suburothelial purinergic receptors which 
consequently enhance bladder activity while NO release seems to decrease detrusor 
contractility (96). However, it is still not clear if the BoNT/A effect on these cells is direct or 
indirect since the presence of SV2 and SNAP-25 on the urothelium is controversial. SNAP-25 
has been described in the urinary bladder after western-blot analysis of full-thickness human 
bladder specimens (59). So far, SNAP-25 expression in the urothelium has never been shown, 
although there is a recurrent mention to this finding without any image to support it (97). 
Concerning SV2, a recent study described the expression of SV2 on a normal urothelial 
cell line (98). This aspect remains to be clarified. A possible but controversial explanation to 
the Onabot/A effect on the urothelium is the cleavage of SNAP-23. SNAP-23 is a homologue 
protein of SNAP-25 essential to the vesicle fusion machinery of non-neuronal cells (99). In vitro 
studies demonstrated that SNAP-23 is a non-neuronal target of botulinum toxin A and E in 
inner medullary collecting duct cells of the kidney (100). Actually, the presence of SNAP-23 was 
already shown in the three urothelial layers of the mouse bladder (101) but if the toxin has the 
ability to cleave the protein in these cells is a question that remains to be answered.  
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5. Botulinum toxin A in the central nervous system 
 
 Botulinum toxin, unlike tetanus toxin, is not considered to undergo retrograde 
transport or transcytosis across neurons, however, some studies seem to contradict that 
consensus. The first studies suggesting a possible central effect of BoNT/A were performed 
after injection of the striated muscle. A study using radiolabeled BoNT/A injected into the cat 
gastrocnemius muscle demonstrated the presence of radioactivity in spinal ventral roots and 
spinal cord segments innervating the injected muscle 48 hours after injection (102). However, 
these studies were never accepted as relevant since it was thought that the toxin molecule 
would reach the CNS without enzymatic activity. Only recently, more studies supported the 
central effect of the toxin (103). Studies from Matak et al reported retrograde transport and 
transcytosis of the toxin into the rat brain facial motor neuron nucleus after administration 
into the whisker muscles. This study showed for the first time that BoNT/A peripheral 
administration could access the central nervous system (104). More recently, other authors 
showed that after BoNT/A injection into the brain tectum, cleaved SNAP-25 was found at least 
two synapses away from the injection site, in rod bipolar cells and photoreceptors (105). Other 
studies that injected BoNT/A in more distant sites, like the sciatic nerve, also observed cleaved 
SNAP-25 immunoreactivity in the ipsilateral dorsal and ventral horns of lumbar segments. The 
same study showed that this transport was microtubule-dependent since it was blocked by 
colchicine (106). 
 Concerning LUT disorders, it should be kept in mind that the afferent signals generated 
by the bladder have to be processed in the CNS. Therefore, the antinociception and the 
general sensory impairment caused by peripheral or central administration of Onabot/A 
should include the impairment of neurotransmitters released from the central sensory 
endings, something that has never been addressed. Thus, studies regarding this aspect on LUT 
disorders are crucial and challenging. 
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Goals 
 
 
The lack of information regarding the targets of botulinum toxin A in the urinary bladder was 
the general base of the present thesis. Thus, aiming to obtain new insights about the 
mechanism of action of Onabot/A in the urinary bladder, the goals of the current work were 
the following: 
 
- Perform a detailed description of the distribution of the high affinity binding site 
and intracellular target of botulinum toxin A on the human and guinea pig bladder 
 
- Analyze the neurochemical content of the nerve fibers affected by Onabot/A in 
guinea pig bladders treated with the toxin 
 
- Evaluate the effect of Onabot/A in the parasympathetic intramural ganglia  
 
- Evaluate the diffusion pattern of Onabot/A through the urinary bladder 
 
- Compare the efficacy of the most common routes of Onabot/A administration 
 
- Investigate the effect of intrathecal Onabot/A in an animal model of bladder pain  
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Abstract
Background: Botulinum toxin type A (BoNTA) has been successfully used in the
treatment of refractory detrusor overactivity. The toxin is internalized after
binding a high-affinity receptor, synaptic vesicle protein 2 (SV2), which is
exposed in the cell membrane during the exocytosis process. In the cytoplasm,
BoNTA cleaves specific sites of synaptosomal-associated protein 25 (SNAP-25),
preventing the assembly of the synaptic fusion complex SNARE and blocking
exocytosis.
Objective: In the present work, the distribution of SV2 and SNAP-25 was first
investigated in human bladders. The neurochemistry of BoNTA-sensitive structures
was then investigated usingmarkers for parasympathetic, sympathetic, and sensory
fibers.
Design, setting, and participants: Human bladders were obtained from cadaveric
organ donors (age range: 19–74 yr).
Measurements: Bladder sections were processed for single or dual immunofluores-
cence staining with antibodies against SV2, SNAP-25, b-3 tubulin, vesicular acetyl-
choline transporter, tyrosine hydroxilase, and calcitonin gene-related peptide.
Results and limitations: SV2 and SNAP-25 immunoreactive fibers were distributed
throughout the suburothelium and muscular layer. Double labeling showed ex-
tensive colocalization of both proteins in nerve fibers. SV2 is more expressed in
parasympathetic fibers than in sympathetic or sensory fibers. No expression was
found in urothelial or muscular cells. Because only normal bladders were used, this
distribution should be applied with caution to pathologic bladders.
Conclusions: SV2 and SNAP-25 colocalize abundantly throughout the urinary
bladder. SV2 is more abundant in cholinergic, parasympathetic fibers. These
nerves are suggested to be themain target for BoNTA action in the human urinary
bladder.
# 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
* Corresponding author. Institute of Histology and Embryology, Alameda Hernani Monteiro, Porto,
4200, Portugal. Tel. +351936046307.
E-mail address: aavelino@med.up.pt (A. Avelino).0302-2838/$ – see back matter# 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.eururo.2009.12.022
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The off-label application of botulinum toxin type A (BoNTA)
in the treatment of lower urinary tract pathologies has
increased noticeably in the last 20 yr. From its initial
application to treat bladder-sphincter dyssynergia, BoNTA
injection in the urinary bladder is now the first option for
the treatment of refractory detrusor overactivity (DO) in
many centers [1–5].
The clinical use of the neurotoxin is based on its ability to
block neurotransmitter exocytosis. Once internalized by
nerve terminals, BoNTA undergoes a pH-dependent con-
formational change that causes the dissociation of its heavy
and light chains. After translocation to the cytosol, the light
chain enzymatically cleaves specific sites of synaptosome-
associated protein 25 (SNAP-25), preventing the SNARE-
mediated fusion of synaptic vesicles with the neuronal
membrane and, thus, blocking neurotransmitter release
[6,7].
The current model to explain preferential internalization
of BoNTA by particular cell types relies on the presence of
high-affinity binding sites for the toxin, namely, synaptic
vesicle protein 2 (SV2), which is a membrane protein
localized in synaptic and endocrine cell secretory vesicles
[8]. During exocytosis, SV2 becomes exposed in the cell
surface, allowing neurotoxin binding and internalization
when vesicle recycling occurs [8].
The overwhelming majority of the studies concerning
the mechanism of action of BoNTA were performed in
striated muscle [9,10]. Thus, despite the increasing use of
BoNTA for treatment of refractory DO, the distribution of
SV2 and SNAP-25 was never systematically studied in the
human urinary bladder. In the present study, we performed
a detailed mapping of SV2 and SNAP-25 expression in the
normal human urinary bladder and investigated the nature
of the positive structures.
2. Materials and methods
2.1. Tissue samples
After receiving permission from of the ethics committee of Hospital S.
Joa˜o, 10 human bladders were collected frommale cadaver organ donors
aged 16, 19, 30, 38, 57 (two), 58 (two), 65, and 74 yr. Blood supply to the
bladder was interrupted during the harvest procedure, between 45 and
60 min before bladder removal.
Bladders were fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer (PB) overnight at 4 8C, washed in PB, and cryoprotected for 24 h in
30% sucrose in PB. Longitudinal 20-mm thick sections from bladder wall
and trigone were obtained in a Microm cryostat, slide mounted in
Superfrost Plus glass slides, and stored at 80 8C for further processing.
2.2. Antibodies
The mouse anti-SV2 antibody [11] was obtained from the Develop-
mental Studies Hybridoma Bank, developed under the auspices of the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development and maintained by the University of Iowa, Department
of Biological Sciences. Rabbit anti-SNAP-25, sheep anti–calcitonin
gene-related peptide (CGRP), and mouse anti-b3-tubulin wereobtained from Abcam plc (Cambridge, UK). Rabbit anti–tyrosine
hydroxilase (TH) was obtained from Chemicon (Millipore [U.K.] Ltd,
Watford, UK). Rabbit anti–vesicular acetylcholine transporter (VAChT)
was obtained from Sigma (Sigma-Aldrich Quimica, S.A., Sintra,
Portugal). The biotinylated donkey anti-mouse was obtained from
Jackson ImmunoResearch (Jackson ImmunoResearch Europe Ltd.,
Suffolk, UK). The biotinylated swine anti-rabbit was obtained from
Dakopatts (Dako Denmark A/S, Glostrup, Denmark). Fluorochrome-
labeled secondary antibodies were obtained from Molecular Probes
Europe (Leiden, The Netherlands).
2.3. Immunolabeling with chromogenic substrate
After thawing, representative sections of each bladder were washed in
phosphate-buffered saline (PBS). After inhibition of endogenous
peroxidase activity (0.3% hydrogen peroxide, 30 min), the sections were
blocked with PBS containing 0.3% Triton X-100 (PBST) with 10% normal
horse serum (NHS) for 1 h, and then incubated in antibodies anti-SV2
(1:2000) or anti-SNAP-25 (1:1000) for 48 h at 4 8C. The avidin-biotin
complex (ABC) horseradish peroxidase (HRP)/diaminobenzidine (DAB)
reaction was performed, as previously described, using biotinylated
species-specific secondary antibodies [12]. Control staining was
performed by omitting the primary antibodies, followed by incubation
with secondary antibodies. Representative images were collected in a
Zeiss Axioscope 40 microscope using the AxioVision 4.6 software.
2.4. Double immunofluorescence labeling
After thawing, sections were permeabilized in 50% ethanol for 30 min,
washed in PBS, and blocked with PBST containing 10% NHS for 1 h.
Incubation with primary antibodies was performed for 48 h at 4 8C. Anti-
VAChT, anti-TH, and anti-CGRP were diluted 1:4000; anti-SV2 and anti-
b3-Tubulin were diluted 1:2000; and anti-SNAP-25 was diluted 1:1000
in PBST containing 2% of NHS. After several washes, the immunoreac-
tions were visualized according to species specificity by Alexa Fluor
488-conjugated donkey anti-rabbit, Alexa Fluor 568-conjugated donkey
anti-mouse, and Alexa Fluor 568-conjugated donkey anti-sheep diluted
1:1000. Controls were performed by omitting primary antibodies.
Representative images were collected in a Zeiss Axioscope 40 micro-
scope using the AxioVision 4.6 software with the appropriate filter sets.
2.5. Counting and statistical analysis
Five representative images taken from full-thickness sections of the
bladder trigone were analyzed per sample. After splitting the red and
green channels, immunoreactive (IR) fibers were counted by super-
imposing a pure color spot on each. The number of spots was then
counted using the Image J software (U.S. National Institutes of Health).
Statistical analysis was performed using the x2 test. A p value of <0.05
was considered statistically significant.
3. Results
A dense SV2 and SNAP-25 networkwas detected both in the
suburothelium and in themuscular layer after the ABCHRP/
DAB reaction (Fig. 1). In the suburothelium, IR structures
formed bundles scattered in the connective tissue and
became progressively thinner as they approached the
bladder lumen. Some were varicose and penetrated the
first layers of urothelial cells (Fig. 1A and C). In themuscular
layer, the positive structures were parallel to the detrusor
smoothmuscle fibers (Fig. 1B and D). These structures had a
morphology similar to nerve fibers andwere also positive to
Fig. 1 – Expression of synaptic vesicle protein 2 (SV2) and synaptosomal-associated protein 25 (SNAP-25) in the suburothelium and muscular layer of
urinary bladder trigone using the avidin-biotin complex (ABC) method. The expression of both proteins is very similar. Immunoreactive fibers in the
suburothelium are present in the lamina propria. Some fibers can be seen penetrating the urothelium (U). In the muscular layer, they are parallel to the
detrusor smooth muscle. Magnification bar: 50 mm for all images.
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neuronal nature (Fig. 2A). No labeling was found in
urothelial or muscular cells (Fig. 1).
Double immunostaining of SV2 and SNAP-25 revealed
abundant colocalization of both proteins throughout the
bladder (Fig. 2B and C).
The distribution of VAChT-, TH-, and CGRP-IR fibers is
shown in Figs. 3A–C and 4A–C. A dense VAChT-IR plexus of
nerve fibers and varicosities was found in the suburothe-
lium (Fig. 3A). In addition, an extensive network of VAChT-
IR fibers coursed the entire thickness of the detrusor smooth
muscle layer (Fig. 4A–C). TH-IR fibers were more abundant
around blood vessels and were rare around smooth muscle
bundles (Fig. 3B). CGRP-IR nerve fibers were sparse in the
suburothelial layer (Fig. 3C) and were rarely found in other
bladder areas, including the detrusor.
VAChT-, TH-, and CGRP-IR fibers and SV2-IR fibers
colocalized at different degrees. Ninety-five percent of
VAChT-IR fibers were also SV2-IR (Fig. 3D). This percentage
was inferior in TH- and CGRP-IR fibers (69% and 58%,
respectively; Fig. 3D).
The percentage of VAChT- and SV2-IR fibers did not show
any major difference, regardless of whether the samples
analyzed came from younger or older subjects; however,the small number of subjects in each age range precluded
statistical analysis.
4. Discussion
SV2 is the high-affinity BoNTA receptor that mediates the
access of the neurotoxin into neurons [8], and SNAP-25 is the
SNARE-complex component that is specifically cleaved by
the toxin [6,8]. To the best of our knowledge, our results are
the first to show a rich SV2- and SNAP-25–IR network in the
human bladder. The neuronal nature of the positive
structures was confirmed by the one-to-one colocalization
between SNAP-25 and the pan-neuronalmarker b-3 tubulin.
SV2 and SNAP-25 showed extensive colocalization, demon-
strating that nerve fibers that have the capacity to internalize
the neurotoxin also express the BoNTA intracellular target.
The present study also demonstrated that SV2 immu-
noreactivity occurs in combination with VAChT, TH, and
CGRP labeling. VAChT is present in cholinergic fibers that
are responsible for the transport of acetylcholine from its
place of synthesis into synaptic vesicles, where is stored
and from which is released. TH is the first enzyme in
catecholamine biosynthesis and catalyzes the conversion
of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA).
Fig. 2 – (A) Double staining for synaptosomal-associated protein 25
(SNAP-25; green) and b-3 tubulin (red) shows abundant colocalization
(yellow-orange). (B,C) Double staining for SNAP-25 (green) and synaptic
vesicle protein 2 (SV2; red). Numerous varicose fibers appear throughout
the detrusor muscle bundles with a high degree of colocalization
between them both (B) in the suburothelium and (C) in the muscular
layer. Magnification bars: 20 mm.
E U RO P E AN URO LOGY 5 7 ( 2 0 1 0 ) 8 8 4 – 8 9 0 887CGRP is a neuropeptide present in small-diameter sensory
fibers. Therefore, colocalization of SV2with VAChT, TH, and
CGRP labeling indicates that the high-affinity protein
necessary for the internalization of BoNTA [8] is presentin parasympathetic, sympathetic, and primary afferent
fibers. Similar colocalization studies were impossible with
SNAP-25, due to the similar species in which SNAP-25 and
the other antibodieswere raised. Taking into consideration
that SNAP-25 and SV2 had a one-to-one colocalization, it is
highly probable that SNAP-25 occurs in VAChT-, TH-, and
CGRP-positive structures.
The distribution of VAChT-IR and TH-IR fibers provided
in this study is similar to that described in previous papers
[13,14]. In fact, a VAChT-IR plexus had been described in the
detrusor and in the suburothelial layer up to the urothelial
base [13], and TH fibers had been found mostly in the
bladder neck [14]. The role of the VAChT plexus, in the
absence of an obvious target, is unclear at the moment but
may be related to the acetylcholine-induced sensitization of
primary afferents previously described in other visceral
organs [15]. Alternatively, other authors described subur-
othelial myofibroblasts in the lamina propria of the bladder,
and these could constitute a possible target for these
efferent fibers [16,17].
CGRP-IR fibers were surprisingly scarce in the human
suburothelium. This finding contrasts with descriptions
available from rodent bladders, so frequently used in
preclinical experiments, in which the CGRP-positive plexus
is extremely dense and occurs not only in the suburothe-
lium but also in the muscular layer [12]. Other studies that
investigated the distribution of neuropeptide containing
sensory fibers in the adult human bladder [18] used small
biopsy specimens, precluding a thorough analysis of fiber
density.
The expression of SV2 in these three nerve subpopula-
tions was surprisingly distinct. SV2 expression was
significantly more abundant in parasympathetic fibers.
This finding may be relevant because it may indicate that
parasympathetic fibers are more susceptible to internaliz-
ing the neurotoxin and thus are more prone to suffer from
its action. The higher colocalization of SV2 in parasympa-
thetic fibers can be related to nerve fiber activity needed to
trigger repeated contractions that are necessary to expel
urine. The relationship between nerve activity and suscep-
tibility to BoNTA poisoning has been shown in the rat
phrenic nerve [19] and in the human skeletal muscle [20].
The frequent acetylcholine release would increase SV2
exposure in parasympathetic nerve terminals, increasing
BoNTA binding.
Surprisingly, no SV2 immunoreaction was found in the
urothelium, making difficult to predict how BoNTA can be
internalized by urothelial cells. It could be possible that
BoNTA penetrates those cells through low-affinity binding
sites [21], but this would not explain how BoNTA could act.
In fact, SNAP-25, the intracellular target, also was not
detected in the human urothelium. Some studies support
the effect of BoNTA on urothelial cells because its
administration decreases adenosine triphosphate (ATP)
release in the bladder [7,22]. However, thismight constitute
an indirect outcome of the neurotoxin treatment rather
than a direct effect on urothelial cells. One characteristic of
BoNTA administration to human bladders is a decrease in
maximal detrusor pressure [2,23]. Interestingly, ATP release
Fig. 3 – Presence of synaptic vesicle protein 2 (SV2) in (A) parasympathetic, (B) sympathetic, and (C) sensory fibers in the suburothelium of the urinary
bladder trigone. SV2 is shown in red; vesicular acetylcholine transporter (VAChT), tyrosine hydroxilase (TH), and calcitonin gene-related peptide (CGRP)
are shown in green. The colocalization between them is represented by yellow-orange. (D) The percentage of parasympathetic fibers (VAChT) that express
SV2 is 95%, higher than the percentage of sympathetic (TH) and sensory (CGRP) fibers, at 69% and 58%, respectively. Comparison of percentages (double-
labeled fibers/single labeled fibers) showed statistical significance. Quantitative data were expressed as mean plus or minus standard error of the mean.
p < 0.05. Magnification bars: 20 mm.
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related to increasing intravesical pressure [24]. Thus, it is
possible that the reduction in maximal detrusor pressure
caused by BoNTA might be the reason for decreased ATP
release.
Our data suggest that only half of bladder sensory fibers
are susceptible to BoNTA. This finding suggests that the
contribution of sensory-fiber impairment for the final effect
of BoNTA in DO is less important than parasympathetic-
fiber impairment. Nevertheless, this finding does not
exclude an effect of BoNTA on sensory function. In fact,
intravesical application of BoNTA is known to reduce
noxious bladder input [7,25], although in some reports,
the effect may be rather transient [3]. BoNTA inhibits CGRP,
substance P, and glutamate release from afferent nerve
endings [22,26]. In addition, BoNTA decreases overexpres-
sion of TRPV1 and P2X3 in the human bladder of patients
with DO [1], most probably by reducing the SNARE-
dependent receptor trafficking [27].
BoNTA should also have targeted sympathetic fibers,
taking into consideration the high degree of colocalizationof TH and SV2. Sympathetic nerve impairment by BoNTA
is accompanied by a decrease in norepinephrine release
[7]. The consequences of BoNTA action in these fibers,
however, should be limited. In the bladder dome and
body, sympathetic fibers induce bladder relaxation. Thus,
sympathetic bladder nerve impairment should increase
detrusor tonus, an effect not observed after BONTA
administration [23].
When considering the limitations of our study, we
cannot ignore that bladders collected from cadaveric organ
donors were presumed to be normal after the lower urinary
tract assessment carried out during the process of donor
selection. It is possible, however, that some, particularly the
elderly donors, could have had DO, taking into consider-
ation the higher prevalence of this urodynamic abnormality
in the general population. Furthermore, it is possible that in
pathologic bladders, the nerve distribution may show
profound differences from the findings described in this
paper. Significant reduction of detrusor innervation occurs
in the obstructed human bladder [28]. Women with DO
were shown to have denser neuropeptide-positive sensory
Fig. 4 – (A–C) Double immunostaining for synaptic vesicle protein 2 (SV2) and vesicular acetylcholine transporter (VAChT) in the muscular layer of
bladder’s trigone taken from donors with different ages. (D) Although no statistical analysis was performed, no major differences were observed in the
number of fibers or in the percentage of colocalization. SV2 is shown in red, VAChT in green. The colocalization between them is shown in yellow-orange.
Magnification bars: 20 mm in all images.
E U RO P E AN URO LOGY 5 7 ( 2 0 1 0 ) 8 8 4 – 8 9 0 889fibers in the suburothelium [18], and TRPV1- and P2X3-
expressing sensory fibers are more numerous in patients
with neurogenic DO [29]. Whether DO exposes more SV2
and facilitates BoNTA binding to parasympathetic fibers is
currently unknown [8,30].
5. Conclusions
SV2 and SNAP-25 immunoreaction is observed in all nerve-
fiber subtypes innervating the humanbladder. SV2, the high-
affinity binding site of BoNTA, is expressed in almost all
parasympathetic fibers but in only half of the sensory fibers
innervating thehumanbladder. Togetherwith the lackof SV2
and SNAP-25 in urothelial cells, our results suggest that the
main mechanism for BoNTA action injected in the bladder
wall is through the impairment of parasympathetic fibers.
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Abstract
Background: OnabotulinumtoxinA (Onabot/A) has been used to treat detrusor overac-
tivity disorders. The treatment is based on several injections of toxin throughout the
bladder wall. However, injection protocols are not well established among clinicians,
varying in dose and dilution.
Objective: Study thedistribution andneurochemistryof cleaved synaptosome-associated
protein of 25 kDa (cSNAP-25) after Onabot/A administration in the guinea pig bladder. In
addition, we analyzed which factor, dose or volume, contributes more to the diffusion of
the toxin.
Design, setting, and participants: Guinea pig bladders were treated with Onabot/A via
intramural injection or an instillation.
Measurements: Bladder cryostat sections were processed for single or dual immuno-
histochemistry staining with antibodies against cSNAP-25, vesicular acetylcholine
transporter, tyrosine hydroxylase, and calcitonin gene-related peptide. Different ad-
ministrationmethods and doseswere analyzed. Statistical analysis was performed using
the chi-square test for colocalization studies after multiple injections and the t test for
the evaluation of affected fibers after a single injection.
Results and limitations: cSNAP-25 immunoreactive fibers were abundant throughout
the bladder tissue in the mucosa and muscular layer. Double labeling showed that
parasympathetic fibers are more affected than sympathetic or sensory. A single Onabot/A
injection ismoreeffective ifdiluted inahighervolume.Onabot/A instillation in thebladder
does not cleave SNAP-25 protein.
Conclusions: A single Onabot/A injection spreads the neurotoxin activity to the opposite
side of the guinea pig bladder. This action is more evident when high saline volumes are
used to dissolve Onabot/A. The toxin cleaves the SNAP-25 protein mainly in cholinergic
but also in adrenergic and sensory fibers. In contrast with intramural injection, instilla-
s not cleave SNAP-25 in nerve fibers.
sociation of Urology. Published by Elsevier B.V. All rights reserved.# 2012 European Astion of Onabot/A doe* Corresponding author. Faculty of Medicine of Porto, Institute of Histology and Embryology,
Alameda Hernani Monteiro, Porto, 4200, Portugal. Tel. +35 1936046307.
E-mail address: aavelino@med.up.pt (A. Avelino).1. Introduction
OnabotulinumtoxinA (Onabot/A) was recently approved for
the treatment of urinary incontinence in patients with
neurogenicdetrusoroveractivity refractory toantimuscarinic0302-2838/$ – see back matter# 2012 European Association of Urology. Publistherapy [1]. The recommended dose of Onabot/A, 200 U, is
injected in 30 different points in the bladder wall above the
trigone, each one receiving 1 ml of normal saline containing
6.7U of toxin [2]. In clinical practice, however, other injection
protocols have been used. Saline volumes vary between 0.1hed by Elsevier B.V. All rights reserved. doi:10.1016/j.eururo.2012.01.046
E U RO P E AN URO L OGY 6 1 ( 2 0 1 2 ) 1 1 7 8 – 1 1 8 4 1179and 0.5 ml per injection site [1,3]. Ten injection sites were
shown to be as effective as 30 [4]. In addition, intravesical
instillation has been suggested as an alternative to bladder
wall injection [5,6], although the capacity of Onabot/A to
cross the intact urothelium was never clearly demonstrated.
The consequences of toxin dilution, injection volume in each
site, or instillation versus injection to the final effect of
Onabot/A were never systematically investigated. This
contrasts with the use of botulinum toxin to treat skeletal
muscle disorderswhere different volumeswere investigated,
showing that larger injections resulted in increased muscle
relaxation [7,8].
Onabot/A cannot be easily traced in the tissues after
injection. To circumvent this problem, magnetic resonance
imaging (MRI) has been used to demonstrate the presence
of the injection fluid in the bladder wall [9]. The presence of
the cleaved form of synaptosome-associated protein of 25
kDa (cSNAP-25), the target protein of the toxin, can be used
as a reliable marker of the neurotoxin diffusion and local
action. Its persistence in the bladder has been suggested as
evidence of botulinum toxin action [10]. Interestingly, the
presence of cSNAP-25 can be easily traced in tissues with an
appropriate antibody [11,12].
In the present work, we characterize the diffusion
pattern of Onabot/A in the guinea pig bladder using the
expression of cSNAP-25 following different injection
volumes and administration protocols. In addition, we also
investigated the time course and the neurochemistry of
fibers expressing cSNAP-25.
2. Material and methods
2.1. Experimental animals
Adult Dunkin-Hartley guinea pigs weighing 400–449 g (Harlan-Iberica,
Barcelona, Spain) were used. All experiments were in accordance with
ECCD (directive 2010/63/EU). All efforts were made to reduce the
number of animals used and treat them humanely.
2.2. Antibodies and reagents
Nonterminal animal handling was performed under ketamine
(6 mg/100 g body weight) and medetomidine (0.025 mg/100 g body
weight) anesthesia via intraperitoneal injection. For terminal handling,
an overdose of sodium pentobarbital was used. Onabot/A was obtained
from Allergan USA. Sheep anticalcitonin gene-related peptide (CGRP)
was obtained from Abcam (Cambridge, UK). Rabbit antityrosine
hydroxylase (TH) was obtained from Millipore (Watford, UK). Rabbit
antivesicular acetylcholine transporter (VAChT) was obtained from
Sigma (Sintra, Portugal). Mouse anti-cSNAP-25 was obtained from R&D
Antibodies (North Las Vegas, UT, USA). The biotinylated horse antimouse
was obtained from Jackson ImmunoResearch (Jackson Europe, Suffolk,
UK). Fluorochrome-labeled secondary antibodies were obtained from
Molecular Probes (Leiden, The Netherlands).
2.3. OnabotulinumtoxinA administration
2.3.1. OnabotulinumtoxinA injection on one single injection point
for studying the spread of cSNAP-25
Male animals (n = 4 per experimental group) were anesthetized and
their bladders exposed by laparotomy. One experimental group receiveda single intramural injection of 2 U of Onabot/A diluted in 2 ml and
another group a similar injection of 2 U diluted in 20 ml of saline. Both
injections were performed in the dorsal side of the urinary bladder
between the entry of the ureters, which were used as a reference point
for subsequent sectioning. Bladders were collected 3 d after administra-
tion. Another four animals were injected with saline and used as
controls. In this experiment, the 2-U dose was selected because, on a
body weight basis, it is similar to the recommended dose for humans.
2.3.2. OnabotulinumtoxinA instillation for studying the spread of
cSNAP-25
Female animals (n = 2 per experimental group) were chosen for
intravesical instillation due to ease of catheterization. Under anesthesia,
2 ml of saline containing 50 U of Onabot/A were instilled through a
catheter inserted in the urethra and kept inside the bladder for 30 min.
Bladders were afterward emptied, washed, and collected 3 d later.
Controls were instilled with saline.
2.3.3. OnabotulinumtoxinA injection on multiple injection points
for cSNAP-25 time course and colocalization analysis
Male animals (n = 4 per experimental group) were anesthetized and a
laparotomy performed. Ten injections of a total of 5 U of Onabot/A
diluted in 200 ml of saline were performed around the entire organ.
Saline-injected animals were used as controls. Bladders were collected
from each group at 6 h, 12 h, 24 h, 3d, and 7 d. In this experiment, our
goal was to perform an image analysis of the presence of SNAP-25 in the
three bladder nerve types. Thus a 5-U dose was selected to affect the
maximum number of fibers.
2.3.4. Tissue fixation
Bladders were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer
(PB) for 4 h at 4 8C and stored in 30% sucrose in 0.1 M PB. A total of
20-mm-thick transverse sections taken from the level of the ureters were
cut in a cryostat, collected in Superfrost Plus slides, and stored at 20C8
until further processing.
2.3.5. Immunolabeling of cSNAP-25 with chromogenic substrate
Detection of cSNAP-25 was performed using the primary antibody
diluted 1:500 for 48 h at 4 8C using the avidin/biotinylated enzyme
complete-horseradish peroxidase method as previously described [13].
Controls were performed by testing the antibody in saline-injected
tissue. Representative images were collected in a Zeiss Axioscope 40
microscope using AxioVision v.4.6 software.
2.3.6. Double immunofluorescence labeling
Bladder sectionswere permeabilized in 50%ethanol for 30 min,washed in
phosphate-buffered saline (PBS), and blocked with PBST (PBS plus 0.5%
Tween 20) containing 10%normal human serum (NHS) for 1 h. Incubation
with primary antibodieswas performed for 48 h at 4 8C. Anti-VAChT, anti-
TH, and anti-CGRPwere diluted 1:4000; anti-cSNAP-25was diluted 1:500
in PBST containing 2%NHS. After severalwashes, antigenswere visualized
using Alexa Fluor 488 conjugated donkey antirabbit, Alexa Fluor 568
conjugated donkey antimouse, and Alexa Fluor 568 conjugated donkey
antisheep, diluted 1:1000. Controlswere performed asdescribed earlier or
by omitting primary antibodies. Images were collected using the
AxioVision v.4.6 software with the appropriate filter sets.
2.3.7. Counting and statistical analysis
2.3.7.1. Bladders injected in a single point and immunolabeled with
chromogenic substrate. From each single injected bladder, six cryostat
sections were analyzed. Each section was totally observed and approxi-
mately 100 photos per section were taken. All cSNAP-25 immunoreactive
(IR) fibers from each photowere visually identified and hand drawn using
[(Fig._1)TD$FIG]
Fig. 1 – Guinea pig bladder diagrams showing the distribution of cleaved synaptosome-associated protein of 25 kDa immunoreactive fibers (dark lines).
A total of 2 U of onabotulinumtoxinA (Onabot/A) diluted in 2 ml (upper diagrams) or 20 ml (lower diagrams) of saline were administered in the indicated
area (syringes). Transverse sections taken at the level of the ureters were analyzed.
E U RO P E AN URO LOG Y 6 1 ( 2 0 1 2 ) 1 1 7 8 – 1 1 8 41180Adobe Photoshop CS. After digital mounting to create a single image of
the entire bladder section, drawn fibers were counted. Statistical
analysis was performed using the t test of GraphPad Prism software.
Values of p < 0.05 were considered statistically significant.
2.3.7.2. Bladders injected in multiple points for immunofluorescence
analysis. For double immunofluorescent colocalization analysis, 10
representative images per animal were analyzed as previously described
[13]. Values of p < 0.0001 were considered statistically significant.Fig. 2 – Average number of immunoreactive fibers for cleaved
synaptosome-associated protein of 25 kDa (SNAP-25) observed per
section after onabotulinumtoxinA (Onabot/A) intramural injection
diluted in 2 ml or 20 ml of saline. Six bladder sections were analyzed per
animal. The difference has statistical significance.
* p < 0.05; error bars show standard deviation.3. Results
3.1. cSNAP-25 distribution after single onabotulinumtoxinA
injections
Three days after a single injection of 2 U of Onabot/A diluted
in 2 ml of saline, scarce cSNAP-25 IR fibers were found in the
bladder wall. This time point was chosen based on results
concerning the time course analysis of cSNAP-25. cSNAP-25
IR fibers were present close to the injection site and
occasionally at more distant areas (Fig. 1). After injecting
the same amount of Onabot/A diluted in 20 ml of saline,
cSNAP-25-IR fibers were more abundant and were present
around the entire perimeter of the bladder, including the
wall opposed to the injection site (Fig. 1). The number of
cSNAP-25-IR fibers was significantly higher in the bladdersthat received Onabot/A diluted in a larger volume (Fig. 2).
Saline-injected animals had no cSNAP-25.
3.2. cSNAP-25 distribution after intravesical
onabotulinumtoxinA administration
In animals receiving Onabot/A by intravesical instillation,
no cSNAP-25 IR structures were found either in the detrusor[(Fig._2)TD$FIG]
[(Fig._3)TD$FIG]
Fig. 3 – Expression of cleaved synaptosome-associated protein of 25 kDa
(cSNAP-25) using the avidin-biotin method after onabotulinumtoxinA
administration (A) through intravesical instillation or (B, C) through an
intramural injection. Dashed lines indicate the boundary between the
urothelium and lamina propria. (a) Animals that received intravesical
instillation of toxin did not express cSNAP-25 either in the urothelium
and mucosa or in the muscular layer. (B) In animals that received an
E U RO P E AN URO L OGY 6 1 ( 2 0 1 2 ) 1 1 7 8 – 1 1 8 4 1181or in the urothelium or lamina propria (Fig. 3A). Because the
results were very consistent in both animals treated, no
more animals were used. In preliminary experiments, no
gender differences were observed in intact SNAP-25
distribution (data not shown).
3.3. Time course of cSNAP-25 and neurochemistry of positive
nerve fibers
cSNAP-25 IR fibers were absent at 6 h but could be detected
in some animals 12 h after Onabot/A. cSNAP-25 IR was
consistently observed at 24 h, with the number of positive
fibers not increasing at 3 and 7 d. In the mucosa, IR fibers
were present in the lamina propria, some of which were
within or immediately below the urothelium (Fig. 3B).
cSNAP-25 IR was not detected in urothelial cells (Fig. 3B). In
the muscular layer, cSNAP-25 IR fibers ran along smooth
muscle bundles (Fig. 3C). Saline-injected animals had no
cSNAP-25.
Double labeling experiments revealed the presence of
cSNAP-25 in the three bladder nerve types analyzed
(Fig. 4A–4C) although in different proportions. At 24 h
cSNAP-25 was expressed in 85% of VAChT-positive cholin-
ergic fibers but only in 42% and 36% of TH-positive
adrenergic and CGRP-positive sensory fibers, respectively
(Fig. 4D). These numbers did not change at 3 and 7 d (Fig. 5).
4. Discussion
It is well established that Onabot/A acts by cleaving the
SNAP-25 protein [14,15]. The cleaved form of the protein
has already been detected in cultured cells [16] and human
bladder tissues by western blot [10] and in rat bladder by
immunohistochemistry [11]. Thus the detection of the
cleaved form of SNAP-25 seems to be a reliable approach to
study nerve fibers or cells affected by the toxin. So far, the
diffusion of the toxin has been estimated by the diffusion of
dyes [17] or contrast agents for MRI [9].
Onabot/A doses used for the treatment of idiopathic or
neurogenic detrusor overactivity has ranged between 100
and 400 U [3]. However, the effect of different injection
volumes was never systematically tested. We evaluated the
diffusion of 2 U injected in one single site of the guinea pig
bladder, which approximately represents an injection of
300 U in a 70-kg patient. We found that for the same dose of
Onabot/A, higher injection volumes cleaved more SNAP-25
and at more distant places. In fact, after 20-ml injection
volume, cSNAP-25 IR fibers were observed throughout the
entire perimeter of the bladder, including the bladder wall
opposed to the injection site. To the best of our knowledge,
no one has ever tried to compare the diffusion of Onabot/A
in the urinary bladder according to injection volume.
However, our data agree with findings in the skeletalintramural injection of toxin, immunoreactive fibers are observed in the
suburothelium present in the lamina propria and in fibers penetrating
the urothelium. In (C) the muscular layer, immunoreactive fibers run
parallel to the detrusor smooth muscle (S). Magnification bars: 50 mm.
[(Fig._4)TD$FIG]
Fig. 4 – Coexpression of cleaved synaptosome-associated protein of 25 kDa (cSNAP-25) (red) with vesicular acetylcholine transporter (VAChT) (A, green),
tyrosine hydroxylase (TH) (B, green), and calcitonin gene-related peptide (CGRP) (C, green) after onabotulinumtoxinA (Onabot/A) administration
throughout the whole bladder. Note the extensive colocalization found between cSNAP-25 and VAChT (A, yellow/orange); (D) quantification of the
coexpression.
*** p < 0.0001. Magnification bars: 50 mm.
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muscle relaxation, indicating a more widespread diffusion
of the toxin [7,8]. One of the factors that may relate to the
more distant diffusion of the toxin may be the easier spread
[(Fig._5)TD$FIG]
Fig. 5 – Percentage of (A) parasympathetic, (B) sympathetic, or (C) sensory fibe
(cSNAP-25) at different time points after onabotulinumtoxinA (Onabot/A) intram
(Onabot/A) injection, the number of cSNAP-25 and the percentage of colocaliza
CGRP = calcitonin gene-related peptide; TH = tyrosine hydroxylase; VAChT = vesof the solution through the connective tissue and muscle
bundles.
We also undertook a detailed analysis of the bladder
structures where cSNAP-25 was expressed. In accordancers that also express cleaved synaptosome-associated protein of 25 kDa
ural injection throughout the whole bladder. After 24 h, 3 d, or 7 d after
tion is unchanged.
icular acetylcholine transporter.
E U RO P E AN URO L OGY 6 1 ( 2 0 1 2 ) 1 1 7 8 – 1 1 8 4 1183with the distribution of intact SNAP-25 observed in human
bladder [13], cholinergic fibers expressed the most cSNAP-
25, in contrast with adrenergic and sensory fibers. At least in
the guinea pig SNAP-25, cleavage is a very fast process.
Within 24 h, the percentage of cholinergic, adrenergic, and
sensory fibers expressing cSNAP-25 had already reached its
maximum, without relevant increases at 48 or 72 h.
In contrast with intramural injections, we could not
detect cSNAP-25-IR fibers following intravesical instillation
of Onabot/A. However, several studies showed that this
method of Onabot/A administration decreases bladder
sensation in humans [18] and reduces the frequency of
bladder contractions in animal models with injured spinal
cords [5,19]. However, in most studies Onabot/A diffusion
was improved either by urothelium disruption with
protamine sulfate [19] or cyclophosphamide [5]. Onabot/A
instillation in the bladder encapsulated in liposomes may
eventually overcome the urothelial barrier and induce
distinctive bladder effects [20].
Onabot/A administration in the bladder has already been
shown to decrease the exocytosis of neuropeptides such as
CGRP and substance P from afferent nerves and of
neurotrophins from the urothelium [21,22]. A decreased
release of nitric oxide and adenosine triphosphate from
urothelial cells after Onabot/A administration to the bladder
is also well demonstrated [21]. In the case of nerve
terminals, the expression of synaptic vesicle protein 2
(SV2) and SNAP-25 iswell documented. Regarding urothelial
cells, the information is scarcer. Available data suggest that
the human urothelium does not express SV2 or SNAP-25
[13]. Likewise, cSNAP-25 was absent from the guinea pig
urothelium.
The most relevant findings of the present study are the
importance of the volume injection to the diffusion of the
toxin and the predominant localization of cSNAP-25 in
cholinergic nerves. Although the latter is relevant for the
toxin mechanism of action, the former is highly pertinent
for clinical practice. If larger injection volumesmay increase
Onabot/A diffusion in the bladder, clinical trials investigat-
ing different injection volumes per site are justified to
investigate a possible enhancement of the toxin effect.
The main limitation of this study was the lack of
correlation between the amount of cSNAP-25 in the bladder
wall with the functional effects of toxin injection. In
addition, results obtained in guinea pigs may not be
directly extrapolated to humans.
5. Conclusions
We showed that Onabot/A injections in the bladderwall can
spread the toxin to areas very distant from the injection
point. This is particularly remarkable when high volumes of
saline are used to dissolve the toxin. When injected, but not
instilled, Onabot/A cleaves SNAP-25 in almost all choliner-
gic nerves and in less than half of the adrenergic and sensory
fibers. Maximal effect is observed rapidly, within 24 h, and
does not increase with time.
These findings suggest that the injected volume is a key
factor in the spread and action of Onabot/A in the bladder,and this may be relevant to improve the clinical effect of
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Effect of OnabotulinumtoxinA on Intramural Parasympathetic
Ganglia: An Experimental Study in the Guinea Pig Bladder
Ana Coelho, Francisco Cruz,* Célia D. Cruz and António Avelino
From the Department of Experimental Biology, Faculty of Medicine and Instituto de Biologia Molecular e Celular (FC),
University of Porto (AC, CDC, AA) and Department of Urology, Hospital S. João (FC), Porto, Portugal
Purpose: We investigated whether onabotulinumtoxinA injected in the bladder
would affect preganglionic parasympathetic nerve endings in intramural ganglia.
Materials and Methods: Guinea pig bladders were injected with 5 U of botuli-
num toxin. At 24 hours bladders were collected and processed for immunohisto-
chemistry using tyrosine hydroxylase, and intact and cleaved SNAP-25. To iden-
tify the different populations of affected fibers coursing the ganglia we performed
double immunoreactions for cleaved SNAP-25 and VAChT, TH or CGRP.
Results: VAChT immunoreactive fibers were identified in axons and varicosities
of presynaptic to postganglionic parasympathetic neurons. Those fibers were also
immunoreactive to SV2 and SNAP-25. The rare CGRP and TH immunoreactive
fibers coursing in the ganglia did not express SV2 or SNAP-25. After onabotuli-
numtoxinA injection the cleaved form of SNAP-25 was abundantly expressed in
parasympathetic fibers.
Conclusions: Botulinum toxin injection in the bladder wall affects preganglionic
parasympathetic nerve terminals. This could contribute to the strong effect of
botulinum toxin on bladder smooth muscle activity.
Key Words: urinary bladder, overactive; onabotulinumtoxinA; ganglia,
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EFFECT OF ONABOTULINUMTOXINA ON INTRAMURAL PARASYMPATHETIC GANGLIA1122glionic cell bodies are located in the ventrolateral
part of the intermediolateral gray matter of the
sacral spinal cord segments.12 Their axons end in
the parasympathetic ganglia, where postganglionic
cell bodies are located. Axons of the latter neurons
mainly innervate the detrusor muscle. Axonal end-
ings from preganglionic and postganglionic neurons
release ACh, which binds nicotinic receptors on post-
ganglionic neurons and muscarinic receptors in
smooth muscle cells.
In humans parasympathetic ganglia are embed-
ded in the bladder wall. Thus, BoNT/A injection in
the bladder might reach not only postganglionic
nerve fibers but also preganglionic terminals in the
ganglia. As a consequence, decreased ACh release
from preganglionic neurons, which is expected to
occur after botulinum administration, together with
inhibited release from postganglionic endings may
contribute to the final effect of BoNT/A on the de-
trusor muscle. Impaired nicotinic cholinergic trans-
mission at the parasympathetic ganglia has pro-
found consequences on bladder function. Ganglion
blocking agents such as tetraethylammonium or
hexamethonium easily induce urinary retention.13
In contrast, muscarinic receptor blockade rarely
causes urinary retention even when high doses are
used.14
Demonstrating that preganglionic parasympa-
thetic neurons become inhibited after BoNT/A injec-
tion into the bladder wall may be difficult in hu-
mans, if not impossible. However, several animal
species used in experimental bladder research15–18
have a parasympathetic organization similar to that
of humans. This is the case in the guinea pig, in
which the current study was done. To provide evi-
dence of the inhibition of preganglionic parasympa-
thetic neurotransmitter release after BoNT/A injec-
tion in the bladder we performed immunodetection
of the cleaved fragment of SNAP-25 in the intramu-
ral ganglia.
MATERIALS AND METHODS
Animals
A total of 14 adult male Dunkin Hartley Guinea pigs
weighing 400 to 450 gm were obtained from Harlan-
Ibérica, Barcelona, Spain. All procedures were done in
accordance with the European Communities Council Di-
rective of 20 September 2010. All efforts were made to
decrease animal stress and suffering, and the number of
animals used. The animals were kept at a 12-hour light/
12-hour dark schedule with free access to food and water.
Well-being was supervised daily.
Reagents and Antibodies
Nonterminal animal handling was performed with the
animals under ketamine (6 mg/100 gm body weight) and
medetomidine (0.025 mg/100 gm body weight) anesthesiavia intraperitoneal injection. For terminal handling ani-
mals received an overdose of intraperitoneal sodium pen-
tobarbital. BoNT/A (OnabotA) was obtained from Aller-
gan, Irvine, California. Mouse anti-SV2 antibody19 was
obtained from the Developmental Studies Hybridoma
Bank. Rabbit anti-SNAP-25 and sheep anti-CGRP were
obtained from Abcam®. Rabbit anti-TH was obtained from
Chemicon®. Rabbit anti-VAChT and anti-neurofilament
200 were obtained from Sigma-Aldrich®. Mouse anti-
cleaved SNAP-25 was obtained from Research and Di-
agnostic Antibodies, North Las Vegas, Nevada. Fluoro-
chrome labeled secondary antibodies and Alexa 488
conjugated CTb were obtained from Molecular Probes®
Europe.
OnabotA and CTB Administration
Ten animals were anesthetized. An abdominal incision
was made and the bladder was exposed. Four animals
received 10 injections evenly distributed in the bladder
wall for a total volume of 200 l saline containing 5 U
OnabotA. Four controls were injected with saline alone.
The other 2 animals were injected in the bladder wall
bilaterally near the entry of the ureters with 5 l 1% CTb
diluted in saline.
Tissue Preparation
Three days after OnabotA administration the animals
were terminally anesthetized. Bladders were harvested,
fixed in 4% buffered paraformaldehyde for 4 hours at 4C
and stored in sucrose 30% in phosphate buffer 0.1M. An-
imals injected with CTb were perfused through the ascend-
ing aorta with Tyrode’s solution (0.12M NaCl, 5.4 mM KCl,
1.6 mM MgCl26H2O, 0.4 mM MgSO47H2O, 1.2 mM
NaH2PO4H2O, 5.5 mM glucose and 26.2 mM NaHCO3),
followed by 4% paraformaldehyde in 0.1M phosphate buf-
fer, pH 7.2. Spinal cord segment S1 was collected, post-
fixed in the same fixative for 4 hours and stored as de-
scribed. Transverse sections (20 M) of the bladder and
spinal cord were cut in a cryostat, collected on Super-
Frost™ Plus slides and stored at 20C until further pro-
cessing.
Immunohistochemistry
After thawing, representative sections of each bladder
were permeabilized in 50% ethanol for 30 minutes,
washed in PBS and blocked with PBS plus 0.3% Triton
X-100 and 10% normal horse serum for 1 hour. Incubation
with primary antibodies was performed for 48 hours at
4C. Anti-VAChT, anti-TH and anti-CGRP were diluted
1:4,000, anti-SV2, anti-intact SNAP-25 and anti-NF200
were diluted 1:2,000 and anti-cleaved SNAP-25 was di-
luted 1:500. All antibodies were diluted in PBS plus 0.3%
Triton X-100 containing 2% normal horse serum. After
several washes immunoreactions were visualized according
to species specificity using Alexa Fluor® 488 conjugated don-
key anti-rabbit, Alexa Fluor 568 conjugated donkey anti-
mouse and Alexa Fluor conjugated donkey anti-sheep, each
diluted 1:1,000. Controls were performed by omitting pri-
mary antibodies. Representative images were collected in
an Axioscope 40 microscope with the appropriate filter
sets using the ApoTome system for optical sectioning and
AxioVision 4.6 software (Carl Zeiss®).
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Intramural ganglia were easily observed in the blad-
der region near the ureters on the serosal surface or
scattered among detrusor smooth muscle bundles.
Postganglionic parasympathetic cell bodies and the
initial segment of axonal processes were strongly
immunoreactive for the neuronal marker NF200
(fig. 1). When simultaneous immunoreaction was
done for VAChT, a protein localized in the axonal
endings of cholinergic fibers,20 strong labeling was
observed in varicose nerve fibers wrapping postgan-
glionic cell bodies (fig. 1). Abundant VAChT staining
was also found in nerve fibers surrounding smooth
muscle bundles (data not shown).
Injecting CTb tracer in the bladder produced ret-
rograde labeling in preganglionic neurons of the in-
termediolateral cell column of the sacral spinal cord
and in postganglionic neuronal cell bodies in the
bladder wall (fig. 2). Punctate staining, consistent
with CTb labeling of nerve terminals, was also ob-
served around postganglionic cell bodies (fig. 2, B).
SV2 and intact SNAP-25 IR was found in nerve
fibers coursing in the ganglia and in terminals im-
pinging on postganglionic cell bodies, showing ex-
tensive colocalization (fig. 3). SV2 and intact
SNAP-25 also colocalized abundantly with VAChT
IR fibers and terminals (fig. 4). In contrast, no colo-
calization was detected with TH and CGRP IR fibers
(fig. 4). Although these fibers were less abundant
than VAChT IR fibers, they were found around gan-
glia or between perikarya. Ganglionic cells did not
express VAChT, CGRP or TH.
In animals treated with OnabotA abundant
Figure 1. Double staining for NF200 (red areas) and VAChT
(green areas) shows NF200 expressed in postganglionic neuro-
nal cell bodies (asterisks) and initial segment of axonal pro-
cesses (arrows), and VAChT in preganglionic nerve fibers and
varicosities wrapping postganglionic perikarya (arrowheads).
Reduced from 20 m.cleaved SNAP-25 IR was detected in ganglia in nerveendings apposed to neuronal cell bodies (fig. 5). As a
control, to show that the antibody against cleaved
SNAP-25 antibody did not recognize the intact pro-
tein tissue from saline injected animals was also
reacted. No signal was observed in these experi-
ments (data not shown). Colocalization analysis be-
tween cleaved SNAP-25 and the 3 nerve types re-
vealed that in ganglia only parasympathetic fibers
expressed the cleaved form of the protein (fig. 5).
DISCUSSION
Organization of the guinea pig bladder parasympa-
thetic innervation is similar to that of humans since
the parasympathetic ganglia of these rodents are
also embedded in the bladder wall.21 In contrast, in
the rat, a more commonly used experimental ani-
mal, the preganglionic fibers do not reach the blad-
der wall since the synaptic contacts are located in
the major pelvic ganglion and, thus, are outside the
bladder. This characteristic of the guinea pig was
reported by Gabella in 1990, who described abun-
dant intramural parasympathetic ganglia in the
equatorial region of the bladder near the entry of the
ureters.21 These observations were fully confirmed
in our study. We further confirmed preganglionic
parasympathetic axonal endings in the guinea pig
bladder wall.
After injecting CTb in the bladder wall this neu-
ronal tracer was transported retrograde to the spi-
nal cord, where it could fill preganglionic parasym-
pathetic cell bodies of the sacral intermediolateral
column.22 These facts made us consider that the
guinea pig was an appropriate experimental animal
in which to answer our initial question.
Figure 2. Retrograde labeling with CTb of neuronal cell bodies
after tracer injection in bladder wall reveals sacral spinal cord
section with labeled motoneurons in intermediolateral cell col-
umn (A), and bladder section with labeled ganglionic neurons
(asterisks) and nerve terminals (arrowheads) (B). DH, spinal gray
matter dorsal horn. Scale bar indicates 50 m.
EFFECT OF ONABOTULINUMTOXINA ON INTRAMURAL PARASYMPATHETIC GANGLIA1124Preganglionic and postganglionic parasympa-
thetic neurons release ACh from their axonal end-
ings. ACh is synthesized in nerve terminals from
choline and acetyl coenzyme A by the cytoplasmic
enzyme choline acetyltransferase. The neurotrans-
mitter is thereafter transported into synaptic vesi-
cles, where it is stored until release. This process
requires a protein called VAChT. We identified
VAChT IR in areas of the central and peripheral
nervous system rich in cholinergic nerve endings,
including sympathetic and parasympathetic gan-
glia.20
Accordingly in this study abundant nerve endings
and varicosities immunoreactive to VAChTwere noted
Figure 3. Double staining for SV2 (red areas) (A) and SNAP-25 (g
areas) (C). Scale bar indicates 20 m.
Figure 4. Co-expression of SV2 or intact SNAP-25 (red areas)
with VAChT (A and B), TH (C and D) and CGRP (E and F) (green
areas). Note extensive colocalization between SV2 or intact
SNAP-25 and VAChT (yellow/orange areas). Scale bar indicates
20 m.in bladder ganglion presynaptic-to-postganglionic neu-
ronal cell bodies and postsynaptically around smooth
muscle fibers. These nerve endings were also immu-
noreactive to SV2, the high affinity binding site for
OnabotA, or to intact SNAP-25, the final target of
the toxin, making them likely targets of OnabotA
action. The same preganglionic nerve endings
showed strong labeling for cleaved SNAP-25 in ani-
mals injected in the bladder with OnabotA. This
indicates that preganglionic parasympathetic termi-
nal axons were also affected by OnabotA delivered in
the bladder wall, fully confirming our initial hypoth-
esis.
The abundant cleaved SNAP-25 in preganglionic
parasympathetic neurons is highly suggestive that
ACh release from these nerve endings should be
significantly decreased after the toxin injection. The
consequence should be decreased cholinergic stimu-
lation of nicotinic receptors in postganglionic para-
sympathetic neurons. The relative contribution of
this finding to the paralyzing effect of OnabotA on
the detrusor muscle can only be an object of specu-
lation. However, ganglionic blocking agents easily
evoke urinary retention, in contrast to muscarinic
receptor antagonists,23 suggesting that parasympa-
thetic preganglionic neuron intoxication can provide
a remarkable contribution to the final effect of On-
abotA on the detrusor muscle.
The number of postganglionic axonal endings and
respective synapses is much higher than the number
of preganglionic ones.24 Thus, complete upstream
blockade of nicotinic transmission seems more likely
than full blockade of the muscarinic transmission,
provided that parasympathetic ganglia are impaired
by the toxin. In clinical practice despite the same
number of injections the exact delivery of OnabotA
may vary, eventually affecting the number of para-
sympathetic ganglia reached by the toxin. This could
contribute to the variability of effects in humans
after OnabotA treatment.4,5
The effect of OnabotA on the human detrusor
muscle lasts an average of 6 to 9 months, twice the
duration of the effect in skeletal muscle.1,3 In the
reas) (B) demonstrates abundant colocalization (yellow/orangereen alatter case only 1 motor neuron is affected. Thus, it
5 and
EFFECT OF ONABOTULINUMTOXINA ON INTRAMURAL PARASYMPATHETIC GANGLIA 1125is tempting to link the longer duration of OnabotA in
the human bladder with the intoxication of 2 syn-
apses. While the OnabotA effect persists at least in
1 of the 2 neurons (preganglionic or postganglionic),
parasympathetic transmission remains impaired.
However, this hypothesis is put forward with cau-
tion. If preganglionic and postganglionic neurons
recover in an equivalent time, the period of de-
creased neurotransmission cannot be doubled, al-
though the 2 neurons are positioned in sequence.
Nevertheless, a BoNT/A effect is expected to occur
until the whole parasympathetic chain becomes
fully operative. To answer this question comparative
studies must be performed of the persistence of
cleaved SNAP-25 in preganglionic and postgangli-
onic fibers.
The physiology of parasympathetic ganglia is far
from being well elucidated. However, enough evidence
has accumulated to state that ganglia are more than a
structure in which only nicotinic cholinergic transmis-
sion occurs. Parasympathetic transmission can be
facilitated or delayed by sympathetic or sensory
nerves, further contributing to the final tuning of
the parasympathetic outflow.25 TH IR detected in
fibers around and in the ganglia in this study was
never noted to our knowledge. Adrenergic recep-
tors in the parasympathetic ganglia had already
been observed on the neuronal surface of gangli-
onic cells,26 explaining the observation that adren-
Figure 5. Co-expression of cleaved SNAP-25 (red areas) with V
tration. Note extensive colocalization between cleaved SNAP-2ergic stimulation modulates parasympathetic flow
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Abstract 
 
There is increasing evidence that botulinum toxin A (Onabot/A) has an antinociceptive 
effect. Indeed, the urinary bladder trigonal injection of the toxin has been shown to reduce 
visceral pain associated with bladder inflammation. The explanation for this antinociceptive 
effect has been attributed to an impairment of neuropeptide release from nociceptive nerve 
terminals. Recent results showed that, in addition, botulinum toxin has an effect on the central 
nervous system that may contribute to this analgesic effect.  
In this work we aimed to study the effect of intrathecal administration of botulinum 
toxin A in an animal model of bladder pain and hyperactivity induced by cyclophosphamide 
(CYP). 
Female rats were subjected to implantation of an intrathecal (IT) catheter at the L6 
segment. Bladder pain was induced by the intraperitoneal (IP) injection of CYP. Four 
experimental groups were created: (1) Saline IT + IP (2) Onabot/A IT (3) CYP + saline IT (4) CYP 
and Onabot/A IT 48h after CYP. Mechanical pain threshold was assessed in the abdomen and 
hindpaws by the von Frey filament test. Motor activity was assessed by measuring the distance 
travelled by rats in an open field arena. Bladder reflex activity was evaluated by cystometry. At 
the end, animals were perfused and bladders and spinal cord collected and immunoreacted 
(IR) against cleaved SNAP-25 (cSNAP-25) and the markers of spinal neuronal activation c-Fos 
and p-ERKs. 
We found that the toxin reduced pain symptoms and the increased bladder reflex 
activity induced by cyclophosphamide. We also observed a direct effect on the expression of 
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
74 
 
neuronal markers of activation, typically up-regulated in this inflammatory model. 
Furthermore we detected the presence of cSNAP-25 not only in nerve fibers throughout the L6 
spinal cord segment but also in the urinary bladder wall in animals treated with Onabot/A. No 
somatic or visceral motor impairments were observed. 
Overall, our results suggest that intrathecal administration of botulinum toxin A has a 
strong analgesic effect in a model of severe bladder pain. This route of administration can be 
further explored to treat intractable forms of pain. 
 
 
Introduction 
 
Botulinum toxin (BoNT/A) administration in the bladder wall is a highly effective 
treatment of neurogenic detrusor overactivity (NDO) (63, 107). Another emerging field in the 
use of BoNT/A is the control of pain, namely that arising from the bladder. Bladder pain 
syndrome/Interstitial cystitis (BPS/IC) is a debilitating condition characterized by an intense 
suprapubic pain associated with increased daytime and nighttime voiding frequency (108). It 
can also be combined with typical cystoscopic and histological features such as edema and 
inflammation (109). The etiology of the disease is still unclear and no effective treatment is 
known. Available treatments are usually focused on the relief of pain but their efficacy is often 
limited (110).  
In a recent study, the injection of toxin in the bladder trigonal area proved to have a 
beneficial effect in BPS/IC patients, decreasing pain and improving their quality of life (66). 
However, this method of BoNT/A administration requires repeated injections controlled by 
cystoscopy every 6-9 months under general anaesthesia. Moreover, injections cause frequent 
urinary tract infections which aggravate BPS/IC symptoms (61, 63).  
Recently, some experimental studies suggested that the intrathecal (IT) delivery of 
BoNT/A has been shown to have a central antinociceptive effect in animal models of 
neuropathic and somatic pain (111, 112). Thus, the IT administration of BoNT/A may also be 
advantageous to treat intractable bladder pain. In the present work we explored this issue by 
using an animal model of bladder pain to determine the effects of IT administration of BoNT/A. 
The analysis concerned the visceral and somatic effects, nociceptive behavior, urinary bladder 
reflex activity and the immunohistochemical observation of cleaved SNAP-25 and spinal 
markers of neuronal activation. 
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Methods 
Animals: All experiments were performed in female Wistar rats weighing 220-250g (Charles 
River, France) that were housed under a 12h light/12h dark schedule with free access to food 
and water prior to experimentation. All procedures were carried out according to the 
European Communities council Directive (2010/63/EU). All efforts were made to reduce the 
number of animals used and their suffering. 
Reagents and drugs: Surgeries for intrathecal placement of a catheter were performed under 
deep anaesthesia induced by intraperitoneal injection (IP) of a mixture of ketamine (6 mg/100 
g body weight) and medetomidine (0.025 mg/100 g body weight) diluted in saline. 
For cystometries and terminal handling animals received a subcutaneous injection of urethane 
(1,2g/kg). Bladder inflammation was induced by a single IP injection of cyclophosphamide 
(CYP; 200mg/kg) (Baxter Medico Farmacêutica, Portugal). Botulinum toxin type A (Onabot/A) 
was purchased from Allergan, Irvine, California. Rabbit anti c-Fos was obtained from 
Calbiochem, UK. Rabbit anti-phospho ERK1/2 protein was obtained from Neuromics, USA. 
Biotin-conjugated swine anti-rabbit was purchased from Dakopatt A/5, Denmark. The avidin-
biotin complex was purchased from Vector, UK. Rabbit anti-GAP43 was obtained from Abcam, 
UK. Anti-cleaved SNAP-25 was a kind gift from Professor Ornella Rossetto from University of 
Padova, Italy. Fluorochrome labeled secondary antibodies were obtained from Molecular 
Probes Europe. 
 
Catheter implantation: Animals (n=6 per experimental group) were deeply anaesthetized and 
a silicon catheter was implanted in the lumbar subarachnoid space as described in previous 
studies (113). A laminectomy was performed between T9 and T10, the catheter was inserted 
and pushed until the tip reached the L5/L6 spinal cord segment. The other tip of the catheter 
was externalized at the forehead for posterior drug delivery. Animals were allowed to recover 
for at least 5 days, during which they were carefully monitored. Data from rats with the 
catheter in an inappropriate position were excluded from the study. 
 
Drug administration: CYP or its vehicle was administered IP at day 0. Forty-eight hours after 
CYP administration, 5 Units of Onabot/A diluted in 50 µl of saline or saline alone was 
administered IT. Animals were divided into four experimental groups: (1) Saline IP + IT, (2) 
Saline IP + Onabot/A IT, (3) CYP + saline IT, (4) CYP + Onabot/A IT. 
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Behavioral Tests: All animals were daily handled, prior to behavioral testing, to avoid stress 
and fear motivated behaviors. To assess cutaneous mechanical sensitivity the Von Frey test 
was used. Rats were placed in individual observation chambers atop a metal mesh floor and 
allowed to acclimatize for 15 min. Cutaneous sensitivity was assessed in the lower abdomen 
and in the hindpaws using von Frey monofilaments (rated at 2, 4, 6, 8, 15, 26, 60 and 100g). 
Filaments were applied for 5 s perpendicularly to the plantar surface and tested 5 times with 
an interval of 30 s between filaments. A response was considered positive when the animal 
reacted to the filament (paw withdrawal or licking) in at least three out of the five filament 
applications. The test was performed at day 0 before any procedure and 4, 24, 48 and 72 h 
after CYP administration or its vehicle. 
In addition, the open field test was performed to seek for any motor impairment that could 
have been caused by surgery or toxin administration. Experiments were conducted in a 
standard open-field maze using a 50x50 cm arena with opaque walls 30 cm high. During the 
test the animals were allowed to explore the maze environment for 5 minutes. An overhead 
video tracking system (CinePlex,Plexon Inc., Dallas, TX, USA) was used to provide information 
about the animal position. Custom MatLab (MathWorks, MatLab release 2009a) and Python 
(version 2.7) in-house software were used to calculate navigation maps. 
 
Cystometries: Animals were anaesthetized and maintained at 37oC using a heating pad. A low 
abdominal middle incision was performed to expose the bladder. To measure bladder reflex 
activity a 21-gauge needle connected to an infusion pump and to a pressure transducer was 
inserted in the bladder dome. Animals were left untouched for 15-30 min to allow bladder 
stabilization. After that time, saline was infused at a constant rate of 6 ml/h and intraluminal 
pressure recorded for 1 hour. The cystometrograms were analyzed using the LabScribe 
software from World Precision Instruments. 
 
Tissue processing: After cystometry animals were perfused through the ascending aorta with 
calcium free Tyrode’s solution (NaCl 0.12M; KCl 5.4 mM; MgCl2.6H2O 1.6 mM; MgSO4.7H2O 
0.4M; NaH2PO4.H2O 1.2 mM; glucose 5.5 mM; NaHCO3 26.2 mM) followed by 4% 
paraformaldehyde in 0.1M phosphate buffer. During tissue collection, the position of the 
intrathecal catheter was verified. Bladder, spinal cord and submandibular salivary glands were 
collected, post-fixed for 4 hours and stored overnight in 30% sucrose in phosphate buffer 
0.1M. Serial transverse sections were cut in a cryostat (20 µM for bladder and 40 µM for spinal 
cord) and collected on Superfrost Plus slides or free-floating on cryoprotective solution. Slices 
were stored at -20oC until further processing. For immunofluorescence, slices were thawed, 
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
77 
 
washed with phosphate buffer containing 0.3% Triton X-100 (PBST) and blocked with 10% 
normal horse serum (NHS) in PBST for one hour. Primary antibodies (anti-GAP43 1:5000 and 
anti-cleaved SNAP-25 1:4000) were diluted in 2% NHS in PBST and incubated for 2 days at 4oC. 
After several washes they were detected according to species specificity using Alexa Fluor® 
labeled antibodies. Sections were mounted in Vectashield mounting medium and observed 
using a Zeiss microscope (Axioimager Z1). Representative images were collected using the 
AxioVision 4.6 software. A minimum of 8 sections per animal was used and the average 
intensity of immunofluorescence for GAP43 analyzed in the dorsal horns using the Fiji software 
(114). Background intensity was subtracted from the average intensity. Detection of c-Fos and 
p-ERK immunoreactivity was visualized using the ABC method (79). After inhibition of 
endogenous peroxidase activity, slices were washed in PBS and PBST and incubated in 10% 
normal swine serum (NSS) in PBST for 1 hour. c-Fos antibody was diluted 1:10000 and p-ERK 
antibody diluted 1:1000, both in 2% NSS in PBST for 48h. Slices were washed and incubated 
with swine anti-rabbit biotin conjugated antibody (1:200). Immunoreaction was visualized with 
0.05% 3,3-diaminobenzidine tetrahydrochloride (DAB) in 0.05 M Tris HCl pH 7.4 plus 0.003% 
hydrogen peroxide. Sections were mounted, air-dried for 12h, cleared in xylene and cover-
slipped. Representative images were collected in a Zeiss Axioscope 40 microscope using the 
AxioVision 4.6 software. Immunoreactive cells for p-ERK or c-Fos were counted in at least 8 
sections per animal and averaged. 
 
Statistical analysis: Statistical analysis of data regarding cystometrogram parameters, open 
field behavior and immunohistochemistry was performed using the one-way ANOVA with 
Tukey’s multiple comparison test. Data are presented as mean +/- standard deviation and p ≤ 
0.05 was considered to be statistically significant. Von Frey results were analyzed using a two-
way ANOVA with Tukey’s multiple comparison test. All statistical analysis was performed using 
the Graph Pad Prism software. 
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Results 
 
1. Intrathecal administration of Onabot/A cleaves SNAP-25 in the spinal cord and in the 
urinary bladder  
The immunohistochemical detection of cleaved SNAP-25 was used to verify the activity of 
Onabot/A via intrathecal administration. Spinal cord segments from C2 to S1 were analyzed in 
terms of the cleaved protein in order to observe the toxin diffusion. Cleaved SNAP-25 
immunoreactivity (IR) was detected in lumbosacral sections from animals that received IT 
Onabot/A (Figures 1, B-D), whereas no IR was found in other experimental groups (Figure 1, A). 
Onabot/A lead to the appearance of a robust cSNAP-25 IR in nerve fibers of the L6 segment 
where the tip of the intrathecal catheter terminated. Cleaved SNAP-25 IR on the L6 segment 
was abundant in the dorsal horn, where most of the urinary bladder afferents reach the spinal 
cord, but also through all the peripheral area of the segment (Figure 1, B). Some labeled fibers 
penetrated deeper in laminae III and IV with long axons projecting through lamina X. Labeled 
fibers were also found in the ventral horn around the cell bodies of motor neurons and in the 
intermediolateral gray matter (ILG) (Figure 1, C). The IR observed in the periphery of the 
sections was still present until L1 but was occasional or absent in thoracic and cervical 
segments. In addition, to exclude a systemic effect of the toxin, the salivary glands, which are 
highly innervated by cholinergic fibers, were also analyzed. No cleaved SNAP-25 fibers were 
observed in those glands (data not shown).  
Finally, as it is known that Onabot/A can have a long-distance effect due to axonal 
transport of the toxin and since bladder projections were being affected, bladder sections 
were also immunoreacted. A few IR-fibers for cSNAP-25 were found scattered in the detrusor 
muscle along the smooth muscle bundles (Figure 1, D). Cleaved SNAP-25 IR was detected 24 
hours after Onabot/A administration and maintained with similar levels of expression for at 
least 30 days. 
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Figure 1: Cleaved SNAP-25 immunoreactivity after IT administration of Onabot/A. Control reaction 
showing no immunoreactivity for cleaved SNAP-25 in a saline injected animal (A). Nerve fibers labeled 
for cleaved SNAP-25 were detected in the superficial laminae of the L6 dorsal horn (B), around the 
motor neuron cell bodies of the ventral horn (C) and around the smooth muscle bundles of the bladder 
wall (D) after administration of intrathecal Onabot/A. Magnification bars represent 50 µm. 
 
2. Intrathecal administration of Onabot/A reduces pain behavior induced by bladder 
inflammation 
Animals injected with CYP showed altered behavior characterized by rounded back, 
immobile posture and closed eyes as previously described by other studies (115, 116). 
Accordingly, inflamed bladders analyzed at the end of the experiment showed evident signs of 
inflammation including petechial hemorrhage on the bladder serosal surface (115). CYP-
induced inflammation is usually associated with an increased cutaneous sensitivity as well as 
referred visceral pain that can be assessed in the hindpaws and in the lower abdominal area 
(117). In the present work, the Von Frey test was used to analyze the cutaneous sensitivity and 
was performed in all experimental groups. Baseline values were obtained 1 week after 
catheter implantation and prior to any further experimentation. No differences were observed 
in animals receiving IP saline irrespective of the intrathecal treatment. For this reason, both 
groups were considered together and are represented in the graph as the non-inflamed 
controls group (Figure 2, A and B). The withdrawal thresholds in non-inflamed animals were 
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similar in both hindpaws and abdomen and were maintained almost constant for the overall 
time course. Immediately after baseline evaluation, animals received a CYP injection or its 
vehicle and the Von Frey test was performed again at 4, 24 and 48 hours after IT injection of 
saline or Onabot/A. A significant decrease in the mechanical threshold was detected in the 
hindpaw and in the abdomen of CYP-injected animals treated with IT saline, starting from 4H 
after CYP and not being altered until the end of the experiment (Figure 2, A and B). A 
significant improvement was observed 24H after Onabot/A injection in CYP-inflamed animals. 
In these animals, mechanical threshold increased to levels similar to control animals. The 
surgery alone and the IT injection of Onabot/A by itself did not alter the hindpaw and the 
abdomen sensitivity (Figure 2, A and B).  
The open field test showed that control animals (naïve or sham-operated animals) walked 
similar distances of approximately 3,5m/min while exploring the arena. Animals submitted to 
intrathecal delivery of Onabot/A exhibited similar behavior, walking similar distances. No 
limping or any other deficits in the motor coordination of the limbs were observed caused by 
either surgery of catheter implantation or by the Onabot/A injection (Figure 2, C). 
 
Figure 2: Pain behavior associated with CYP-induced inflammation. Intrathecal administration of 
saline or Onabot/A in non-inflamed animals did not induce any alteration in the mechanical sensitivity in 
the abdomen and hindpaw. For this reason and for increased clarity of the graph they were grouped 
together and are represented as the non-inflamed controls group. Animals receiving CYP injection 
showed a significant decrease in the mechanical threshold in both areas analyzed. Onabot/A IT 
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administration (arrows) increased the threshold to levels similar to the non-inflamed controls (Figure 2, 
A and B). Asterisks indicate significant differences between the CYP-inflamed and non-inflamed animals 
(*p≤0.05, **p≤0.01, *** p≤0.001 and ****p≤0.0001). The open field test showed no differences in the 
distance traveled by naïve, sham-operated or Onabot/A injected animals (Figure 2, C). Error bars show 
the SEM.  
 
3. Intrathecal administration of Onabot/A decreases urinary frequency induced by 
bladder inflammation 
On the last day of experiments, cystometric recordings were obtained from all 
experimental groups. Intact animals that received saline or Onabot/A showed normal reflex 
activity (0.35±0.04 and 0.47±0.05 contractions/min, respectively) (Figure 3, A and B). CYP-
induced inflammation increased urinary frequency (0.82±0.09 contractions/min) and reduced 
the intercontraction intervals (Figure 3, C and E). On the other hand, IT Onabot/A 
administrated to CYP-inflamed animals counteracted the increased urinary frequency 
associated with the CYP injection (0.41±0.28 contractions/min) (Figure 3, D and E). 
Macroscopically, no differences were observed in the size of the bladders that could suggest 
an increased post-void residual volume after toxin administration. Also, no differences were 
found in other cystometric parameters analyzed (peak pressure and area under the curve) 
(Figure 3, F and G). 
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Figure 3: Cystometrograms depicting urinary bladder reflex activity. Non-inflamed animals treated with 
Saline (A) or Onabot/A (B) exhibited normal reflex activity. Inflamed animals showed an increased 
urinary frequency (C). Onabot/A IT administration in inflamed animals decreased the urinary frequency 
to values similar to the non-inflamed animals (D). Urodynamic parameters evaluated during cystometry 
procedure are represented in the graphs E to G. Evaluation of the micturition frequency showed 
increased activity in the inflamed group without toxin administration (E). No differences were found in 
the peak pressure (F) and area under the curve (G) among experimental groups. Data is represented as 
mean ± SEM. **P < 0.01 was considered statistically significant. 
 
4. Intrathecal administration of Onabot/A reduces c-Fos and p-ERK immunoreactivity 
induced by bladder inflammation 
In normal animals a modest amount of p-ERK IR cells (14.99±1.11) were observed 
bilaterally in laminae I-II, in the dorsal commisure (DCM, around lamina X) and in the 
intermediolateral grey matter (ILG) as already showed by previous studies (113) (Figure 4, A 
and E). IR occurred in both the nucleus and the cytoplasm as well as along the neuronal 
processes. The injection of Onabot/A by itself did not increase the number of IR cells in any 
area of the sections (13.69±1.13) (Figure 4, B and E). The basal activity of p-ERK, induced by 
cistometry, was substantially increased in CYP animals (31.66±4.97) (Figure 4, C and E). In 
these, IR cells exhibited long axons that crossed the lamina X until the other side of the 
section. However, the injection of Onabot/A in animals with CYP-induced inflammation 
showed a decrease of IR cells throughout the L6 segment to levels similar to the controls 
(19.82±2.14) (Figure 4, D and E). 
As described before (118), c-Fos expression was detected in the lumbosacral spinal cord 
mainly in the lamina I, in the ILG and in the DCM (41.8±3.37) (Figure 5, A, B and E). Onabot/A 
injection in saline animals did not change the basal number of c-Fos cells (49.17±3.35). CYP-
induced inflammation significantly increased the number of IR cells throughout the described 
areas (100.4±11.97) (Figure 5, C and E). As observed above, the injection of Onabot/A in 
animals with CYP-induced inflammation showed a decrease of IR cells throughout the L6 
segment to levels similar to the controls (58.64±5.18) (Figure 5, D and E). 
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Figure 4: Photomicrographs of the L6 spinal cord segment showing the distribution of p-ERK 
immunoreactive cells. Animals that received an intrathecal injection of either saline or Onabot/A exhibit 
similar number of p-ERK IR cells on the spinal cord (A and B). The number of IR cells was significantly 
increased in animals with CYP-induced inflammation (C). Administration of Onabot/A in inflamed 
animals showed that the number of p-ERK IR cells was similar to that found in non-inflamed animals (C 
and D). Graph depicts the average number or p-ERK IR cells found in the L6 spinal cord segment (E). Data 
is represented as mean ± SEM. **P < 0.01. Magnification bars represent 50uM. 
 
Figure 5: Photomicrographs of the L6 spinal cord segment showing the distribution of p-ERK 
immunoreactive cells. Animals that received an intrathecal injection of either saline or Onabot/A exhibit 
similar number of c-fos IR cells on the spinal cord (A and B). The number of IR cells was significantly 
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increased in animals with CYP-induced inflammation (C). Administration of Onabot/A in inflamed 
animals showed that the number of c-fos IR cells was similar to that found in non-inflamed animals (C 
and D). Graph depicts the average number or c-fos IR cells found in the L6 spinal cord segment (E). Data 
is represented as mean ± SEM. **P < 0.01. Magnification bars represent 50uM. 
 
 
5. Intrathecal administration of Onabot/A did not alter GAP43 immunoreactivity 
In normal animals, the L6 segment of the spinal cord exhibits a discrete IR for GAP43 in 
nerve fibers of dorsal horn superficial laminae, in the DCM dorsally to the central canal, in the 
dorsolateral funiculus, in the corticospinal tract and in the ILG (Figure 6, A and E). In CYP-
inflamed animals, the intensity of GAP43 IR is clearly increased in the described areas (Figure 
6, C and E). IT delivery of Onabot/A, in either saline or CYP-inflamed animals, did not alter the 
expression of GAP43 (Figure 6, B, D and E). 
 
 
 
Figure 6: Distribution of GAP43-IR in the L6 segment by fluorescence microscopy. GAP43-IR intensity is 
increased during CYP-induced inflammation (C) when compared to animals without inflammation (A and 
B). After IT delivery of Onabot/A the intensity of GAP43-IR was maintained high in levels similar to the 
CYP-inflamed animals (D). The average intensity of IR is graphically represented for each experimental 
group (E). Data is represented as mean ± SEM. *p≤0.05, **P < 0.01. 
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Discussion 
 
In the present study we used the CYP-induced model of bladder inflammation that 
mimics bladder pain observed in BPS/IC patients. CYP is metabolized in the liver to acrolein, an 
irritant compound that is excreted in the urine, eliciting an extreme bladder inflammation. 
CYP-inflamed animals showed clear signs of pain such as rounded back posture, piloerection, 
closed eyes and lowered mechanical sensitivity (119). Intrathecal delivery of Onabot/A in 
animals with CYP-induced inflammation rapidly improved pain behavior and cutaneous 
sensitivity in the abdomen and hindpaws. Our results are, therefore, in line with recent studies 
that suggested an antinociceptive effect of the toxin after its IT administration. Indeed, the IT 
administration of Onabot/A reduced the formalin-induced nociceptive responses in mice 
during 21 days (85, 111, 112). Likewise, it significantly decreased thermal and mechanical 
hypersensitivity induced by diabetic neuropathy, an effect that started within 24 hours and 
lasted for almost one month (111). On the other hand, our results also corroborate other 
studies showing the peripheral administration of Onabot/A exerting an indirect effect on the 
central nervous system. Cui et al showed that Onabot/A administration in the rat hindpaw 
decreased inflammatory pain induced by formalin, along with a decrease of Fos-like 
immunoreactive cells in the dorsal horn (85). 
Concerning urinary bladder reflex activity, the IT administration of Onabot/A 
counteracted the increased urinary frequency associated with CYP-induced inflammation 
without causing urinary retention. At the best of our knowledge, this is the first study that 
shows an effect of IT delivery of toxin on bladder function. 
In addition to these physiological findings, we also found changes in the expression of 
cleaved SNAP-25 as its immunohistochemical detection has been used as an indicator of 
Onabot/A activity  (120). Nerve fibers labeled with cleaved SNAP-25 were primarily detected in 
the L6 segment of the spinal cord. Immunoreactivity was found mainly in the periphery of the 
sections but also in laminae I and II, in some fibers deeper in the dorsal horn and in the ventral 
horn, in fibers surrounding the cell bodies of motor neurons. IR gradually decreased in spinal 
cord segments more rostral or caudal than L6 being scarce in the thoracic and sacral segments 
and inexistent in the cervical segments. This strong IR in the cord periphery could be explained 
by toxin diffusion, since this area is in contact with the cerebrospinal fluid. A systemic effect 
was excluded since observation of salivary glands, highly innervated by cholinergic fibers, did 
not show any cleaved SNAP-25 IR. On the other hand, some labeled fibers were detected in 
the urinary bladder coursing the smooth muscle bundles, a fact that requires another 
explanation rather than diffusion. The presence of cleaved SNAP-25 in the urinary bladder 
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could only be explained if axonal transport occurred. Actually, this hypothesis has been already 
suggested in other studies, which found cleaved SNAP-25 in areas distant from the delivery site 
of Onabot/A that was suppressed by colchicines (104, 105, 121-123). However, in the majority 
of studies, the axonal transport was retrograde from the peripheral to the central nervous 
system (104, 105, 123) or anterograde but in a small distance from the optic tectum to retinal 
cells (124). In the present work we showed for the first time that the axonal transport is bi-
directional since it also occurs from the CNS to the periphery. 
Furthermore, we verified the effect of Onabot/A in the pain-related sensory pathways 
where ERKs activation and Fos expression occur. The appearance of phosphorylated ERKs 
occurs in the spinal cord after somatic and visceral noxious stimulation (113). Likewise, the 
detection of the immediate early gene c-Fos is commonly used to detect noxious sensory input 
generated in the bladder and conveyed to the spinal cord and its activity correlates with ERK 
activation (125). We showed that Onabot/A decreased the CYP-induced expression of c-Fos 
and phosphorylated ERK, suggesting an indirect effect of the toxin. Botulinum toxin affects the 
anchoring of fusion vesicles with the plasma membrane. It affects channel availability by 
decreasing the trafficking of at least a well known receptor implicated in pain pathways, the 
TRPV1 receptor (84). If the insertion of this receptor in the plasma membrane is decreased, it 
could be speculated that, through this pathway, botulinum toxin decreases neuronal activity in 
the spinal cord. Thus, our data corroborate previous results showing a pronounced effect of 
the toxin in central sensory pathways, justifying the beneficial effects observed in pain and 
urodynamic parameters. Additionally, all these observations are temporally correlated with 
the appearance of cleaved SNAP-25 in the spinal cord suggesting that the protein cleavage 
might be the trigger that initiates all other outcomes. 
No effects were observed in the GAP43 IR upregulation after Onabot/A administration. 
GAP43 is a neuronal growth-associated protein that is usually up-regulated during neuronal 
injury, regeneration and synapse formation (126). An increase of GAP43-IR has been described 
in the lumbosacral segments of the spinal cord in rat models of bladder inflammation (127). 
Thus, we confirmed the distribution of this protein and analyzed if Onabot/A could alter GAP43 
expression. We found that the expression of this marker was increased in the L6 segment 
during bladder inflammation possibly due to an attempt of sensory fibers to recover from the 
injury caused by bladder inflammation (127). However, Onabot/A did not counteract this 
effect suggesting that the factors responsible for GAP43 upregulation during inflammation are 
not dependent on exocytosis but rather on non-vesicular pathways. 
To discard any negative effect on the somatic motor function caused by the intrathecal 
placement of the catheter or the toxin administration, the open field test was performed. No 
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impairments were observed since animals walked similar distances at similar speed while 
exploring the field. This is in accordance with other studies which performed the rota-rod test 
to check the neurotoxicity of Onabot/A IT administration, showing no differences when 
compared to controls (112). 
 
 
Conclusion: 
We verified that Onabot/A IT administration has a powerful antinociceptive effect in 
an animal model of bladder pain. The toxin acts by direct cleavage of SNAP-25 protein in the 
CNS but also through an indirect effect on central pain pathways. This intrathecal route of 
toxin delivery should be further studied due to its potential application in cases of intractable 
pain. 
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Final Considerations 
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1. Distribution of SV2 and SNAP-25 in the human bladder 
The first important outcome of the present thesis was the mapping of SV2 and SNAP-25 
expression in the human bladder (Publication I). So far, this was the first systematic and 
detailed description of both proteins in this organ. The only previous study of SNAP-25 in the 
urinary bladder was limited to small biopsies of bladder dome from NDO patients (128). In the 
present work both proteins were shown to be present exclusively in nerve fibers throughout 
the whole organ suggesting that an entire neuronal net can be potentially targeted by BoNT/A. 
As the urinary bladder is innervated by three different neuronal populations it would be 
important to analyze to which population the targeted fibers belonged.  
The expression of SV2 and SNAP-25 was observed in parasympathetic, sympathetic and 
sensory fibers. Ninety-five percent of the parasympathetic fibers population possessed SV2 
and SNAP-25 which was not surprising since Onabot/A injections in the human bladder 
decrease bladder frequency (73). This is in accordance with the BoNT/A effect on the striated 
muscle where cholinergic terminals are affected and muscular contraction impaired (34). This 
fact might also indicate that parasympathetic fibers are more susceptible to BoNT/A because 
its activity is required to initiate the detrusor voiding contractions and maintain the tonic 
activity. In addition a permanent sympathetic fiber activity might occur to promote detrusor 
relaxation. This connection between nerve activity and the degree of intoxication has already 
been addressed in the rat phrenic nerve where a higher nerve fiber activity led to faster nerve 
intoxication (24). Furthermore, both SV2 and SNAP-25 proteins were found in sympathetic and 
sensory fibers in considerable amounts, 69% and 58%, respectively. This result corroborates 
previous studies where the toxin was able to decrease the release of neuropeptides and 
transmitters typically present in non-cholinergic fibers (90). 
Another important aspect of the first work was the absence of SV2 or SNAP-25 expression 
in the urothelium of human bladders. This is a controversial finding since other authors 
detected both SNAP-25 and SV2 in urothelial cells (97, 98). In both studies their presence was 
observed by RT-PCR, a technique considered more sensible than immunohistochemistry, which 
could explain the different results. However, their expression was very low and did not prove a 
direct effect of the toxin in these cells. In addition, technical issues could also be the reason for 
such difference since SNAP-25 was detected in mucosa samples that might include nerve 
endings and in urothelial cell lines that could differentiate during culture (Birder L, in press). 
Hence, the results of publication I, demonstrated for the first time that all types of urinary 
bladder nerve fibers are potential targets of the toxin action.  
MECHANIMS OF ACTION OF BOTULINUM TOXIN IN THE TREATMENT OF OVERACTIVE BLADDER 
 
 
92 
 
 
2. Distribution of the cleaved form of SNAP-25 after botulinum toxin administration 
Although the essential proteins for Onabot/A action were expressed throughout the 
human bladder there was no direct evidence that all the nerve populations were actually 
affected if the toxin was applied. Thus, our next step was the histological analysis of urinary 
bladders previously injected with Onabot/A. For this purpose, guinea pig bladders were used 
since it was impossible to perform this analysis in human bladders (Publication II).  
First, we confirmed if the expression of SV2 and SNAP-25 was in accordance with what had 
been observed in our previous work on the human bladder. Indeed, both proteins showed a 
distribution throughout the organ and expression levels in the three neuronal populations 
similar to that in human bladders.  
The effect of Onabot/A on the guinea pig bladder was detected through the analysis of the 
cleaved form of SNAP-25. It is well established that BoNT/A cleaves SNAP-25 (6) and this 
cleaved form had been detected before in cultured cells (18) and human bladder biopsies (59) 
after treatment with BoNT/A. Thus, we considered the detection of cleaved SNAP-25 a reliable 
and accurate approach to study the activity of Onabot/A. 
After Onabot/A administration in guinea pig bladders, a detailed analysis of all bladder 
structures was carried out. Cleaved SNAP-25 was detected throughout the whole detrusor 
muscle and on the three neuronal populations studied. Parasympathetic fibers were the most 
affected as 85% of them expressed cleaved SNAP-25. Sympathetic and sensory fibers also 
expressed the cleaved form but in lower amounts (42% and 36%, respectively), showing an 
widespread effect of the toxin on the three neuronal populations.  
The effect of the toxin was shown to be very fast since the maximum density of affected 
fibers was observed within 24 hours and lasted for at least 7 days without changes (Publication 
II). 
These results clearly support recent basic and clinical evidences that suggest an effect of 
BoNT/A on all urinary neuronal pathways. BoNT/A is known to target efferent pathways, 
blocking ACh release and consequently decreasing smooth muscle contractility. This effect can 
be very pronounced as it causes urinary retention in some NDO patients (63, 64). BoNT/A 
effect on sensory pathways is already well supported since it improves urgency symptoms in 
OAB patients (61-64) as well as bladder pain in BPS/IC patients (66). Finally, its effect on the 
sympathetic pathways is still a matter of debate. However, recent studies already showed a 
decrease on the urinary noradrenaline levels in BPS/IC patients treated with Onabot/A (129).  
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3. Diffusion of botulinum toxin through the urinary bladder 
During the last years, many clinical trials have been performed concerning the beneficial 
effects of Onabot/A in LUT disorders. However, different protocols were used without a 
systematic study concerning site of injections, number of injections, dilutions or toxin doses 
leaving several to be answered (67). As an example of how important injections can be, 
recently, Kuo et al compared the therapeutic effects of different intramural injections. His 
patients reported the same outcome after detrusor, submucosal or trigonal injections 
regarding detrusor overactivity. However, injections on the trigone rather than the dome 
relieved urgency symptoms without affecting bladder capacity (130). 
In publication II we aimed to clarify some of these questions by addressing two important 
issues that were ambiguous. We started to address the effect of Onabot/A administered 
through two different approaches already tested in clinical trials: the intramural injection and 
the intravesical instillation. Animals who received an intramural injection of toxin showed 
fibers labeled with cleaved SNAP-25 throughout the whole bladder, as described in the section 
above. On the other hand, animals that underwent intravesical instillation of the toxin showed 
no labeled fibers, neither in the urothelium, nor in the detrusor. This finding could be 
controversial since many studies reported beneficial effects of Onabot/A after intravesical 
instillation (68, 131, 132). However, it should be noted that in those studies the urothelial 
barrier was disrupted by either protamine sulfate (131) or cyclophosphamide (68), eventually 
allowing the contact of toxin with the bladder interstitium. Since we never observed SV2 or 
SNAP-25 in the urothelium and considering that Onabot/A has a high molecular weight we 
could speculate that urothelial disruption would be the only mechanism allowing the contact 
of the toxin with bladder nerve terminals. 
The second issue we addressed was the effect of the injected volume in the activity and 
diffusion of the toxin. Thus, we evaluated the diffusion of a single Onabot/A injection using 
two different volumes. We found that using the same dose in a higher volume more fibers 
containing cleaved SNAP-25 could be detected. Additionally, it was also observed a higher 
spread throughout the organ. These results show that the volume is a key factor to be 
considered when performing Onabot/A injections which is in accordance with similar studies 
performed in striated muscle where bigger volumes of injection induced more relaxation of 
the muscle due to a higher diffusion of toxin (133, 134). 
Publication II showed relevant findings for both basic and clinical research fields. The 
finding that Onabot/A cleaves SNAP-25 predominantly in cholinergic nerves but also affects 
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the other neuronal populations added more information about the mechanism of action of the 
toxin. From the clinical point of view, the finding that the injection of larger volumes of the 
same toxin dose increased Onabot/A diffusion and efficacy is of extreme importance for the 
design of future clinical trials. 
 
 
4. Effect of Onabot/A on the bladder intramural ganglia 
The advantage of using the guinea pig as a model instead of the commonly used rat is 
related with its LUT anatomy. In the guinea pig, as in humans, the parasympathetic ganglia 
that receive efferent information from supraspinal areas are embedded in the bladder wall 
(135). Here, preganglionic axonal terminals establish synapses with the postganglionic cell 
bodies that innervate the detrusor. Both nerve terminals release ACh and are located within 
the bladder wall. Sympathetic and sensory innervation also surrounds the ganglia, exerting 
inhibitory or excitatory effects that might modulate its activity (136). Therefore, it would be 
expected that the intramural administration of botulinum toxin would affect more than one 
cholinergic synapse, a double-action that would contribute to the final effect of the toxin. 
Actually, the effect of ganglioplegic agents that block nicotinic transmission in the human 
bladder has strong consequences on bladder function. These agents easily cause urinary 
retention, a consequence rarely seen if only the postganglionic muscarinic transmission is 
impaired (137, 138). 
In Publication III we started to identify the location of the three neuronal populations 
around the ganglia. Parasympathetic fibers were found coursing the ganglia and impinging to 
the ganglionic cell bodies. Sympathetic and sensory fibers were scarce and found mainly 
around the ganglia. Further, SV2 and SNAP-25 was observed in the in nerve fibers coursing the 
ganglia with a total co-localization. In contrast to what was observed in the nerve fiber 
network throughout the organ, after Onabot/A administration, cleaved SNAP-25 was detected 
exclusively in parasympathetic fibers. 
The results obtained showed that Onabot/A in the urinary bladder affects preganglionic 
and postganglionic terminals at the same time. Since both nicotinic and muscarinic 
transmission might be impaired, it is expected that the toxin action, as it happens with the 
ganglioplegic agents, exerts a stronger effect in the detrusor. Based on these results, we could 
speculate that this double inhibition could explain the longer duration of effect of Onabot/A in 
the smooth muscle when compared to the striated muscle. However, this hypothesis should 
be taken with caution since a direct correlation between both facts was not performed. 
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It is well known that sympathetic and sensory fibers found inside parasympathetic ganglia 
modulate nicotinic parasympathetic transmission. Botulinum toxin might be expected to 
impair sympathetic and sensory fibers, however, the paucity of their number makes a 
definitive statement of their function after toxin application impossible.  
 
 
5. Effect of Onabot/A during bladder inflammation 
The antinociceptive effect of botulinum toxin has been a major topic of pain research in 
the last years. Recent studies showed that peripheral administration of Onabot/A in the rat 
hindpaw was able to reduce symptoms of both inflammatory and neuropathic pain (85, 123). 
Concerning the urinary bladder, intramural injection of Onabot/A reduced pain symptoms and 
improved urodynamic parameters along with a reduction in the urinary levels of NGF and 
BDNF in refractory BPS patients (66).  
Recently, intrathecal (IT) administration of botulinum toxin type A was shown to be 
effective in the treatment of peripheral pain. Actually, Onabot/A administered intrathecally in 
mice, attenuated inflammatory pain induced by formalin for 21 days (112). In addition, it 
significantly decreased thermal and mechanical hypersensitivity induced by diabetic 
neuropathy, an effect that started within 24 hours and lasted for almost one month (111). 
These improvements in peripheral pain were attributed to the decreased spinal cord 
expression of CGRP, p-ERK and p-CaMK (112) thus suggesting a central antinociceptive effect 
of the toxin.  
In the present study we investigated the effect of IT Onabot/A in a well established animal 
model of bladder inflammatory pain. In these animals, nociceptive behaviour and mechanical 
sensitivity are increased, as we confirmed with the Von Frey test. In addition, bladder reflex 
activity of inflamed animals is significantly altered, with an increased frequency and decreased 
maximum bladder capacity. This phenomenon is attributed to an increased activity of 
nociceptive primary afferents (139). The IT administration of Onabot/A counteracted the effect 
of bladder inflammation, decreasing the mechanical sensitivity of the hindpaw and abdomen 
as well as the urinary frequency, to levels similar to the controls.  
Furthermore, we investigated the presence of cleaved SNAP-25 in the L6 segment of the 
spinal cord, the main termination area of bladder primary afferent neurons. After IT delivery of 
toxin, cleaved SNAP-25 was observed throughout the L6 segment mainly in the periphery and 
in the dorsal horn but also around cholinergic neurons of the ILG. 
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The presence of cleaved SNAP-25 in the spinal cord has already been shown in previously. 
In these studies, toxin was administered in peripheral somatic locations such as the hindpaw, 
the gastrocnemius muscle and the sciatic nerve. Afterwards, the cleaved protein was observed 
along the L3 to L5 segments of the spinal cord in small cholinergic fibers with long neuronal 
processes and in the dorsal horn. Thus, the results suggested an axonal transport of the toxin 
from the periphery to the central nervous system (106). In our study, besides the appearance 
of cleaved SNAP-25 in the spinal cord after IT delivery of toxin, the cleaved protein was also 
detected in the urinary bladder. Thus, to the best of our knowledge, our studies were the first 
to report the axonal transport of the toxin from the CNS to the peripheral nervous system. 
In our work, we also observed other effects of Onabot/A on the spinal cord. Several 
studies described that CYP-induced inflammation is responsible for an increased expression of 
CGRP, GAP43, c-fos and p-ERKs at the lumbosacral level (113, 127, 140). Thus, in addition to 
the previous goals, in Publication IV we also described the effect of IT Onabot/A in the 
expression of these markers. We first observed that the intrathecal placement of the catheter 
or the Onabot/A injection by themselves did not induce any alteration in the basal levels of 
these markers. We also confirmed a significant increase of their expression in the spinal cord 
of inflamed animals. Finally, we confirmed our hypothesis that locally applied Onabot/A would 
decrease the expression of CGRP, c-fos and p-ERKs by impairing sensory neurotransmission in 
animals with bladder inflammation indicating a strong analgesic effect.  
In the course of our studies no effects were observed in the expression of the GAP43 
protein after IT Onabot/A in inflamed bladders. This increase is in accordance with previous 
studies (127). GAP-43 protein is associated with functional recovery of nerve terminals from 
the neuromuscular junction after botulinum toxin A treatment (141) so, it could be expected 
that IT administration of Onabot/A would also increase its expression. However, in contrast 
with what was obtained in the skeletal muscle, where Onabot/A induces a strong sprouting of 
neuronal terminal endings, we did not detect changes in the GAP-43 IR in the spinal cord 
Onabot/A treated animals.   
Thus, IT Onabot/A clearly has an effect on the modulation of pain pathways in both the 
peripheral and central levels. 
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From the results obtained in the present work, the following conclusions were withdrawn: 
1. The receptor and the intracellular targets of botulinum toxin A are expressed in the 
three types of nerve fibers present in the human and guinea pig bladder.  
 
2. The cleaved form of SNAP-25 could be detected in the three types of bladder nerves 
analyzed after intramural injection of botulinum toxin A in the guinea-pig bladder. 
 
3. The volume is a key factor in the efficacy of botulinum toxin injections that should be 
considered in the improvement of clinical protocols.  
 
4. Botulinum toxin applied intramurally in the urinary bladder affects pre and post 
ganglionic parasympathetic synapses. This fact might be the reason for the longer 
duration of the toxin effect observed in the smooth muscle. 
 
5. Intrathecal administration of botulinum toxin improves bladder function and pain 
associated with chemical-induced bladder inflammation. The intrathecal delivery of 
botulinum toxin could be considered an alternative and effective treatment for 
bladder pain syndrome.  
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